feature,importance,feature_group
num__base_rate,0.41640024757385574,numeric
num__rate_vs_trial_start,0.38862981478657266,numeric
num__recency_decay,0.1585170743863947,numeric
num__discontinued_n,0.02289562607961605,numeric
num__enrollment_count,0.002163719239855371,numeric
num__completed_n,0.0019094792320190435,numeric
num__total_sites,0.0019007611410440575,numeric
num__size_factor_log1p_started,0.0015537953899670276,numeric
num__started_n,0.0014586845865446568,numeric
num__num_countries,0.0014248930410595108,numeric
cat__period_title_Overall Study,0.0005186634224615907,categorical
cat__search_condition_cardiovascular disease,0.0004422621507573797,categorical
cat__reason_Progressive Disease,0.00034502458027273783,categorical
cat__reason_Death,0.000316126901296783,categorical
cat__arm_id_FG000,0.0002863995828265084,categorical
cat__arm_id_FG001,0.00026296829598741566,categorical
cat__search_condition_heart failure,0.00017514524347876816,categorical
cat__arm_id_FG003,0.00017134785915512058,categorical
cat__period_title_Part 2 Double Blind Epoch,0.00010304767995330867,categorical
cat__reason_Adverse Event,9.707883023688232e-05,categorical
cat__period_title_Treated Participants,8.978045943204022e-05,categorical
cat__reason_End of data collection,5.278663941448608e-05,categorical
cat__reason_Disease progression,3.179046731112604e-05,categorical
cat__search_condition_diabetes type 2,2.5804145040315474e-05,categorical
cat__reason_Withdrawal by Subject,1.7801140596575765e-05,categorical
cat__search_condition_hypertension,1.6434975948981036e-05,categorical
cat__arm_id_FG004,1.5860414352311086e-05,categorical
cat__reason_Disease Progression,1.535339803339925e-05,categorical
cat__reason_Subject withdrawn-to commercial product,1.4082859143634541e-05,categorical
cat__reason_Reason not specified,1.0490585256710678e-05,categorical
cat__reason_Lack of Efficacy,8.975503008117102e-06,categorical
cat__reason_Other,8.84957963099065e-06,categorical
cat__sponsor_class_INDUSTRY,7.65360420137713e-06,categorical
cat__period_title_Initial Treatment Period,7.311337439294137e-06,categorical
cat__search_condition_obesity,6.880437459559943e-06,categorical
cat__reason_Lost to Follow-up,6.609379192557595e-06,categorical
cat__arm_id_FG002,6.336951022924869e-06,categorical
"cat__reason_Patient refusal to continue, not due to adverse event",6.265523943158389e-06,categorical
cat__reason_Study specific discontinuation criteria,6.199236283422814e-06,categorical
cat__period_title_Double-blind Segment 2,5.443891627875356e-06,categorical
cat__reason_Protocol Violation,4.422828607031204e-06,categorical
cat__reason_Abnormal test procedure result(s),4.025949293560303e-06,categorical
cat__reason_Reason not Specified,3.912915476961966e-06,categorical
cat__sponsor_class_NETWORK,3.849083243396079e-06,categorical
cat__period_title_Discontinuation From Treatment,3.0880002370988096e-06,categorical
cat__period_title_Study 306B,2.8351617959264342e-06,categorical
cat__reason_Progression of disease,2.8259879259442476e-06,categorical
cat__period_title_Treatment Period,2.6728593098928654e-06,categorical
cat__sponsor_class_NIH,2.342177348535282e-06,categorical
cat__sponsor_class_OTHER,2.3027980589265877e-06,categorical
cat__period_title_Part 1 Open Label Epoch- Period 1,2.270150995103303e-06,categorical
cat__reason_Relapse or Progressive Disease,1.8926917332130416e-06,categorical
cat__period_title_Active Treatment Phase,1.7923038483834958e-06,categorical
cat__reason_Consent withdrawn by subject,1.7761400631605174e-06,categorical
cat__period_title_Part A (Run-in - 2 Weeks),1.7101506324322483e-06,categorical
cat__reason_Early termination,1.662775841316641e-06,categorical
cat__period_title_Open Label Treatment Phase,1.6091846826667288e-06,categorical
cat__period_title_Treatment,1.4901692039275254e-06,categorical
cat__period_title_Open Label Extension,1.4896253538672811e-06,categorical
cat__period_title_Initial Treatment Phase (Weeks 0 - 12),1.478156055730921e-06,categorical
cat__search_condition_dyslipidemia,1.271601266980352e-06,categorical
cat__period_title_On Study at Time of Unblinding,1.0640764154463662e-06,categorical
cat__reason_Termination of Trial,9.150944179373711e-07,categorical
cat__period_title_Double-blind Period,8.958574358773946e-07,categorical
cat__period_title_Treatment Period (TP) (156 Weeks),8.86958239203299e-07,categorical
cat__reason_Perceived Lack of Efficacy,8.6660709593466e-07,categorical
cat__period_title_Long-Term Follow Up Phase,8.570237695087111e-07,categorical
cat__period_title_Extension Phase,8.304353846380766e-07,categorical
cat__reason_Continue in Long Term Follow Up,8.060199554425345e-07,categorical
cat__period_title_Blinded Treatment Phase,7.036963160762281e-07,categorical
cat__period_title_Core Part of Study,6.396373858509612e-07,categorical
cat__reason_Unclassified,6.204663504499557e-07,categorical
cat__reason_Study terminated by sponsor,5.745007841559212e-07,categorical
cat__reason_Patient Request,5.620740663239793e-07,categorical
cat__reason_Study drug toxicity,4.561277178291092e-07,categorical
cat__reason_Administrative discont. at study termination,4.256526405940623e-07,categorical
cat__period_title_Double-Blind Period,3.17564210282555e-07,categorical
cat__reason_Ongoing in study,2.578482181531215e-07,categorical
cat__period_title_30-week Core Treatment Period,2.4692161166181253e-07,categorical
cat__reason_Physician Decision,2.1651537007271264e-07,categorical
cat__reason_Decision by Participant or Proxy,1.925622061478659e-07,categorical
cat__reason_Adverse event unrelated to study drug,1.8847047993597774e-07,categorical
cat__period_title_Controlled Treatment Period (CTP),1.8569017396996505e-07,categorical
cat__reason_Participant moved to open-label extension (OLE) study,1.8479939085430406e-07,categorical
cat__reason_Hyperglycemic Rescue,1.8376208000900084e-07,categorical
cat__reason_Pretreatment Event/Adverse Event,1.6088857927368406e-07,categorical
cat__reason_Hyperglycemic rescue,1.381509729242243e-07,categorical
cat__reason_Withdrew Consent,1.323157755594697e-07,categorical
cat__reason_Other reasons,1.1948890464781656e-07,categorical
cat__reason_Consent withdrawn,1.188658775607128e-07,categorical
cat__period_title_Before Randomization (VCD Induction),1.141668122014574e-07,categorical
cat__period_title_Phase B (Weeks 24-104),1.0559524532709051e-07,categorical
cat__period_title_Short Term (ST) + Long Term (LT) Period,8.77344516579686e-08,categorical
cat__sponsor_class_FED,8.241934232856788e-08,categorical
cat__period_title_Double-blind (DB) Phase,8.152016664595239e-08,categorical
cat__period_title_Double-blind (DB) Treatment Period,7.76012991965766e-08,categorical
cat__reason_Reversible ischemic defect not present,7.75867871922694e-08,categorical
cat__period_title_Treatment Period (156 Weeks),7.406260811590003e-08,categorical
cat__period_title_Year 2 (Week 0 to Week 104),6.955364898946278e-08,categorical
cat__period_title_Cohort 1,6.936354469175619e-08,categorical
cat__period_title_Active Treatment Phase (Weeks 13-64),6.450480569421218e-08,categorical
cat__reason_Other than specified above,6.055666827749135e-08,categorical
cat__reason_Subject Withdrew Consent,5.555825871516585e-08,categorical
cat__reason_Withdrawal Criteria,5.1615470412027405e-08,categorical
cat__period_title_Main Study (Up to Wk 96),4.6875912869257954e-08,categorical
cat__reason_Participant request,4.583893248323094e-08,categorical
cat__reason_did not continue in extension,4.498671271790945e-08,categorical
cat__period_title_Main Period: Week 0 to Week 56,4.440375922519281e-08,categorical
cat__reason_Study specific discontinuation criteris,4.4306995333107634e-08,categorical
cat__reason_Other reason not stated above,4.088846149445332e-08,categorical
cat__period_title_Part B (2 Year Core Study),4.047376347594667e-08,categorical
cat__reason_Other reason (not specified),3.7521647890435584e-08,categorical
cat__reason_Only Vital Status Known,3.4799287865375586e-08,categorical
cat__period_title_Follow-up Period,3.4489877289364054e-08,categorical
cat__period_title_Pharmacology Intervention/Randomization,3.106532070698203e-08,categorical
cat__period_title_48-month Short Term + Long Term Period,2.982803690970375e-08,categorical
cat__period_title_Phase B,2.9248361435964656e-08,categorical
cat__reason_lost to follow-up for all-cause death,2.855821245093459e-08,categorical
cat__period_title_Double Blind Period (103 Weeks),2.7922610696730732e-08,categorical
cat__reason_Miscellaneous,2.774005113636972e-08,categorical
cat__period_title_Study Completion,2.7455300047949708e-08,categorical
cat__period_title_Precrossover: Periods I/II (Weeks 1-12),2.7275580749952437e-08,categorical
cat__period_title_Extension Open Label Treatment,2.37665231368163e-08,categorical
cat__period_title_Treatment Phase (Overall Study),2.3552687428420717e-08,categorical
cat__period_title_Extension Study - up to 3 Years,2.347238299308101e-08,categorical
cat__period_title_Safety Follow-up Period,2.287771275694478e-08,categorical
cat__period_title_Up to Final Analysis (Week 52),2.1784060073678024e-08,categorical
cat__reason_Did not enter OLC,2.0422540464203747e-08,categorical
cat__reason_Withdrawal of Consent,2.0237607476639292e-08,categorical
cat__period_title_Extension Phase (Wk 96 to Wk 156),2.02116776503722e-08,categorical
cat__reason_Missing end-of-study page,1.9196649352232947e-08,categorical
cat__reason_Voluntary Withdrawal,1.887348919632644e-08,categorical
"cat__reason_Refusal to continue, not due to AE",1.6643834507449223e-08,categorical
cat__period_title_Part 1: Blinded Period,1.6416176474362683e-08,categorical
cat__period_title_Core,1.593231211410402e-08,categorical
cat__period_title_Year 1 ( Week 0 to Week 52),1.5873121240714136e-08,categorical
cat__period_title_Part 2 (Week 24 to Week 72),1.5808033305044922e-08,categorical
cat__period_title_Primary Treatment Period,1.5663026888068862e-08,categorical
cat__period_title_Period 1 (Baseline - Week 52),1.4975342864605337e-08,categorical
cat__reason_Other Reasons,1.4441323580940092e-08,categorical
cat__arm_id_FG005,1.42767127080588e-08,categorical
cat__period_title_Weeks 0-56,1.3269186519111397e-08,categorical
"cat__period_title_Randomized, Completed 6 Months of Study",1.228273032094126e-08,categorical
cat__reason_Withdrawal criteria,1.2075736113078634e-08,categorical
cat__reason_Oral anticoagulant required,1.2026082616102675e-08,categorical
cat__period_title_Maintenance Period (Week 20 to Week 68),1.1835728916978207e-08,categorical
cat__reason_GCP violations,1.1346884863306252e-08,categorical
cat__reason_Withdrawal of consent,1.1160659725816987e-08,categorical
cat__reason_Alive,1.078954536370976e-08,categorical
"cat__reason_Patient refusal to cont., not due to AE",1.0714411850057923e-08,categorical
cat__reason_Other Adverse Event (AE),1.0446866322155921e-08,categorical
cat__period_title_Treatment Phase,9.962170298331218e-09,categorical
cat__reason_Potassium Withdrawal Criteria Met,9.788207399885792e-09,categorical
cat__reason_Subject decision,9.756363956913767e-09,categorical
cat__period_title_OLE Part of Study,9.29008541908941e-09,categorical
cat__period_title_Core Period: Baseline to Week 26,9.197624949662197e-09,categorical
cat__reason_Other Reason,8.644086760301543e-09,categorical
cat__period_title_Core Study - 16 Weeks,8.405287044958054e-09,categorical
cat__reason_Other than specified,8.24567429746877e-09,categorical
cat__search_condition_metabolic syndrome,7.95364754958975e-09,categorical
cat__search_condition_NASH,7.645002366255527e-09,categorical
cat__reason_Any other reason,7.636425898230735e-09,categorical
"cat__reason_Adverse event, non-fatal event",7.595832189105904e-09,categorical
cat__period_title_Follow-up Period (8 Weeks),7.595111071899267e-09,categorical
cat__period_title_Double-blind Study Period (Week 36 - 92),7.165830680625289e-09,categorical
cat__period_title_Open Label Phase,7.105923395900814e-09,categorical
cat__period_title_Double-Blind Treatment Phase,7.05786360065413e-09,categorical
cat__period_title_Primary Study (Through Year 1),7.045743089554722e-09,categorical
cat__period_title_Non-treatment Follow-up Period,7.004122154506487e-09,categorical
cat__period_title_603B: 24-36 Week Study Period,6.961983845429645e-09,categorical
cat__period_title_Discontinuation From Study (Treated Set),6.825546376968516e-09,categorical
cat__period_title_Run-in Phase,6.602273537285403e-09,categorical
cat__period_title_2 - Enrolled Participants Set,6.4429985713230905e-09,categorical
cat__reason_Investigator-Initiated Early Closure,6.35504781534502e-09,categorical
cat__period_title_Extension Period: Week 26 to Week 52,5.67735347608599e-09,categorical
cat__period_title_24-week Double-blind Treatment Period,5.6457475500207005e-09,categorical
cat__period_title_Follow-Up Period,5.6352174432913124e-09,categorical
cat__reason_discontinued in preceding trial,5.505339963006767e-09,categorical
cat__reason_Voluntary withdrawal,5.359466064922798e-09,categorical
cat__reason_Only one reason for discontinuation,5.337312294532573e-09,categorical
cat__reason_Non compliant with protocol,5.152478996317316e-09,categorical
cat__period_title_Double Blind Placebo Controlled (DBPC),5.102312049740545e-09,categorical
cat__reason_No reason for withdrawal,4.9721935122201016e-09,categorical
cat__period_title_Main Study,4.959259578471414e-09,categorical
cat__reason_Protocol deviation,4.819342567698068e-09,categorical
cat__period_title_LT Period,4.806892663872797e-09,categorical
cat__reason_Noncompliance,4.761977111740876e-09,categorical
cat__reason_Other - as reported by the investigator,4.701623839822328e-09,categorical
cat__period_title_Main Trial Period Through Week 56,4.635472802427268e-09,categorical
cat__period_title_LTOLE Part (Open Label),4.606696950338854e-09,categorical
cat__reason_Poor compliance to protocol,4.597260993204015e-09,categorical
cat__period_title_Discontinuation From Trial,4.470082170034171e-09,categorical
cat__reason_Clinical Adverse Event,4.468300201817405e-09,categorical
cat__period_title_Period II,4.298265255571648e-09,categorical
cat__period_title_Phase A (Weeks 0-24),4.263399673133364e-09,categorical
cat__period_title_Double Blind Treatment Period,4.243284618455595e-09,categorical
cat__period_title_Long-term Treatment Period,4.094960824736242e-09,categorical
"cat__period_title_Single Blind(Run-in Period, 4 Weeks)",4.048352510494372e-09,categorical
cat__period_title_Weeks 0-20,4.020492924148087e-09,categorical
cat__period_title_Follow-up Period (FUP) (8 Weeks),3.973918968895881e-09,categorical
cat__reason_Physician withdrew consent,3.5259412873491857e-09,categorical
cat__reason_did not complete year 4 follow-up,3.4538351929225437e-09,categorical
cat__reason_Unsatisfactory therapeutic effect,3.397566267888422e-09,categorical
cat__period_title_603A: 0-12 Week Study Period,3.3434814080860517e-09,categorical
cat__reason_Protocol Specified Discontinuation,3.3089678904167327e-09,categorical
cat__reason_Other Serious Adverse Event,3.2977987914427417e-09,categorical
cat__reason_Participant decision,3.0585034887875734e-09,categorical
cat__period_title_DB Treatment Period-Randomized Patients,2.9921703065942612e-09,categorical
cat__period_title_Treatment Period 2 (Week 16 to Week 31),2.9169463822620238e-09,categorical
cat__period_title_1st Stage,2.8803358879838148e-09,categorical
cat__reason_At the Participant's own request,2.606524429451102e-09,categorical
cat__period_title_Treatment Period 2,2.593639559996816e-09,categorical
cat__period_title_Period 1,2.5075355163684737e-09,categorical
cat__reason_Reason Not Specified,2.394165910157251e-09,categorical
cat__period_title_Weeks 20-54,2.379289458837924e-09,categorical
cat__period_title_OLEX Period (up to 48 Weeks),2.2628732772843166e-09,categorical
cat__reason_Subject withdrew consent,2.169763138659947e-09,categorical
cat__reason_Lost to follow-up to primary endpoint,2.1422251312952837e-09,categorical
cat__reason_Reduced creatinine clearance,2.0778020996693083e-09,categorical
cat__reason_Other than those specified,2.050622102676108e-09,categorical
cat__reason_Hyperglycemia,2.0242152444312584e-09,categorical
cat__period_title_Main + Extension Period: Week 0-172,1.9972293711538417e-09,categorical
cat__period_title_Additional Treatment Period,1.9960101760227688e-09,categorical
cat__reason_Patient withdrew consent,1.9713615455446536e-09,categorical
cat__reason_Reasons other than stated above,1.9128277475458565e-09,categorical
cat__period_title_Entered - Long-Term Extension Study,1.8606270208986796e-09,categorical
cat__period_title_Uncontrolled Treatment Period (UTP),1.8361760343887309e-09,categorical
cat__reason_Investigator Decision,1.7347909184783708e-09,categorical
cat__reason_Other non serious Adverse Event,1.7157694384185816e-09,categorical
cat__reason_Study site terminated by sponsor,1.6741382369672291e-09,categorical
cat__period_title_Core Study,1.6645487045925518e-09,categorical
cat__period_title_Lead-in,1.6517521027787539e-09,categorical
cat__period_title_Week 52,1.6350238223333734e-09,categorical
cat__reason_Other reason not defined above,1.6311481773290765e-09,categorical
cat__period_title_Treatment Period (52 Weeks),1.609274967624829e-09,categorical
cat__reason_Death or Transplant,1.5748128858272914e-09,categorical
cat__period_title_Short-term Treatment Period,1.5078204498124494e-09,categorical
cat__period_title_Core Period: 26 Weeks,1.506967105698821e-09,categorical
cat__reason_Related to study drug administration,1.4063646539429178e-09,categorical
cat__reason_Decision by Sponsor,1.4051614836642597e-09,categorical
cat__period_title_Extension Period,1.404812943991783e-09,categorical
cat__period_title_Placebo-controlled Withdrawal (Phase 2),1.3661197879349969e-09,categorical
cat__reason_Did Not Enter Follow-up Period,1.356795359199015e-09,categorical
cat__period_title_Period 1: Short-term (24-week) Phase,1.316447408283625e-09,categorical
cat__reason_Missing final visit,1.3045097798159518e-09,categorical
cat__reason_Dropped,1.299696179057756e-09,categorical
cat__period_title_Open Label Titration,1.2505475563318976e-09,categorical
"cat__reason_Sponsor Decision, Arm Discontinued",1.197387584722479e-09,categorical
cat__reason_Lack of therapeutic response,1.1921063879517614e-09,categorical
cat__period_title_Period 2 (Week 52 - Week 104),1.1756280243282206e-09,categorical
"cat__reason_non-compliance, not met criteria, etc.",1.1330144364820198e-09,categorical
cat__reason_Withdrawal of consent by subject,1.1148177364316642e-09,categorical
cat__period_title_Single-blind Period (2 to 4 Weeks),1.0943684464816035e-09,categorical
"cat__period_title_Double-Blind, 6 Months",1.088845060075749e-09,categorical
cat__reason_No Endpoint Blood Draw,1.0335982006604118e-09,categorical
cat__period_title_1 -Modified Enrolled Participants Set,1.028640138157241e-09,categorical
cat__reason_Major Protocol Deviation,1.0021684648188797e-09,categorical
cat__period_title_Lead-In Period,9.886068834670778e-10,categorical
cat__period_title_24-week Short-term Treatment Period,9.815974669608002e-10,categorical
cat__period_title_After Randomization (TP and VTP),9.60860899088193e-10,categorical
cat__reason_patient's private reason,9.417431980042532e-10,categorical
cat__period_title_Long-term Follow-up Period,9.390723618919537e-10,categorical
cat__period_title_8-week Double-blind Period,9.215850585233332e-10,categorical
cat__period_title_Initial 3 Month Counseling,9.082411967665842e-10,categorical
"cat__reason_Withdrawal of Consent,Protocol Deviation",8.983326151643576e-10,categorical
cat__reason_No study drug received,8.851511786427828e-10,categorical
cat__period_title_Main Treatment Period,8.381248666110486e-10,categorical
cat__reason_Condition under investigation worsened,8.350472277511098e-10,categorical
cat__reason_Non-compliance with study medication,8.341635847492739e-10,categorical
cat__period_title_Transfer Treatment Phase (Weeks 12 - 24),8.286362192408176e-10,categorical
cat__reason_Selection Criterion/Protocol Violation,8.251451191384167e-10,categorical
cat__reason_Other - As Reported by Investigator,8.245578128208856e-10,categorical
cat__period_title_Main: Week 0 to 26 (NN5401-3590),8.239314225533715e-10,categorical
cat__reason_Patient refused to take study medication,8.079399978247428e-10,categorical
cat__period_title_Part 1 (Baseline up to Week 24),8.02217438083973e-10,categorical
cat__period_title_Double-Blind,7.987807066855594e-10,categorical
cat__period_title_26-week Treatment Extension Period,7.557389924675701e-10,categorical
cat__reason_Other withdrawal reason,7.539292752517677e-10,categorical
cat__period_title_Open-Label,7.403103215561753e-10,categorical
cat__period_title_Open Label Treatment Period,7.340641060006965e-10,categorical
cat__reason_Not true myocardial infarction,7.246744482010382e-10,categorical
cat__reason_Study closed by sponsor,7.209285331463259e-10,categorical
cat__reason_Other adverse events (non-serious),7.146440418002396e-10,categorical
cat__period_title_Variable Treatment Period,6.990974037507701e-10,categorical
cat__period_title_Phase A,6.93002704497159e-10,categorical
cat__arm_id_FG007,6.814657566854833e-10,categorical
cat__arm_id_FG006,6.611078181514116e-10,categorical
cat__reason_Delayed visit and insufficient study,6.584312366835844e-10,categorical
cat__period_title_Blinded Treatment (Up to 03 Aug 2005),6.579109941928818e-10,categorical
cat__period_title_Main Period (MP) (up to 16 Weeks),6.568349309776305e-10,categorical
cat__period_title_26 Week (Short Term),6.525290570249263e-10,categorical
cat__period_title_Part 1,6.42923797585149e-10,categorical
cat__period_title_Dose Response Phase (Phase 1),6.374904172900926e-10,categorical
cat__period_title_Treatment Period II: Week 12 to Week 36,5.795085486037986e-10,categorical
cat__period_title_Up to Unblinding (07 Jun 2005),5.654342846371591e-10,categorical
cat__reason_Lack ofEfficacy / Physician Decision,5.63402434490312e-10,categorical
cat__reason_Study closed/terminated,5.581973874458612e-10,categorical
cat__period_title_Post-Treatment Safety Follow-Up Period,5.551432400634778e-10,categorical
cat__reason_Clinical endpoint reached,5.353325238029271e-10,categorical
cat__period_title_Part 2,5.253957402919278e-10,categorical
cat__reason_Pregnancy,5.043227033416187e-10,categorical
cat__period_title_Observational Period,4.894723293484017e-10,categorical
cat__reason_Surgery initiated before infusion,4.869621270926536e-10,categorical
cat__reason_Major protocol deviation,4.865139501692197e-10,categorical
cat__reason_Missing follow-up information,4.682736145030473e-10,categorical
cat__reason_Amendment 4: > Month 12,4.4512431298520434e-10,categorical
cat__reason_Indirect contact,4.2125292859569097e-10,categorical
cat__reason_missed closeout visit,3.9282779731888476e-10,categorical
cat__reason_H.A. Request,3.9232826255816113e-10,categorical
cat__reason_Assigned Treatment by Mistake,3.8254171620118996e-10,categorical
cat__reason_Investigator discretion,3.6867981979059125e-10,categorical
cat__period_title_Period III,3.5464637354650474e-10,categorical
cat__period_title_Interventional Phase,3.469040545029522e-10,categorical
cat__reason_Consent withdrawn by participant,3.3319949701223246e-10,categorical
cat__reason_Subject/guardian decision,3.310113089867e-10,categorical
cat__reason_major GCP violations,3.222739664261452e-10,categorical
cat__period_title_Treatment Period 3 (Week 32 to Week 52),3.140245425097109e-10,categorical
cat__reason_never received study drug,3.132854904555198e-10,categorical
cat__reason_Site closure,3.116416023808044e-10,categorical
cat__reason_Other: Not related to COVID-19,3.040968192949458e-10,categorical
cat__period_title_Observational Follow-up,2.988596121165514e-10,categorical
"cat__reason_Patient refusal to continue,not due toAE",2.9569561278956343e-10,categorical
cat__period_title_Period VI (Open-Label),2.9415059016525875e-10,categorical
cat__period_title_Intensification Period (Week 26-38),2.8350988429151804e-10,categorical
"cat__period_title_Main Period, Weeks 0-26",2.8192039313285995e-10,categorical
cat__period_title_Study 306A,2.8112870348831405e-10,categorical
cat__reason_Site closure: Final VS available,2.757373294566202e-10,categorical
cat__reason_Poor Compliance to Protocol,2.7573616110322663e-10,categorical
cat__period_title_Crossover: Period III (Weeks 13-20),2.7414287368876036e-10,categorical
cat__period_title_Double-blind Phase (18 Months),2.737542942470763e-10,categorical
cat__period_title_Part 1 Double-Blind,2.6814426437973225e-10,categorical
cat__period_title_Cohort 2,2.662964348574163e-10,categorical
cat__reason_Withdrawal by Parent/Guardian,2.6547864291583176e-10,categorical
cat__period_title_Period 1: 24-Week Double-blind Treatment,2.5850091921320116e-10,categorical
cat__reason_Subjects Did Not Complete Week 36,2.4106602981756193e-10,categorical
cat__period_title_Open Label Extension Phase (12 Months),2.4102091107851084e-10,categorical
cat__period_title_First Period (First 6 Months),2.401038954784009e-10,categorical
cat__period_title_44-week Open-label Extension,2.3444836518865313e-10,categorical
cat__reason_Hyperglycemia Meeting Discontinuation Criteria,2.330399442916616e-10,categorical
cat__period_title_Phase II,2.328768246392827e-10,categorical
cat__period_title_Placebo Controlled Phase (Weeks 0-12),2.3147337532888372e-10,categorical
cat__reason_LostToFollowUpfor3P-MACE(StatusUnknown),2.2897920776312523e-10,categorical
cat__period_title_Extension: Week 27 to 52 (NN5401-3726),2.260623706303483e-10,categorical
cat__reason_Qualifying condition not present,2.2329033073167962e-10,categorical
cat__reason_Lab abnormalities,2.2296897129027338e-10,categorical
cat__period_title_Completed Study Follow Up,2.1973021450748035e-10,categorical
cat__reason_Unable to take rescue therapy,2.193767189047042e-10,categorical
cat__period_title_54-Week Base Study,2.1412285923465445e-10,categorical
cat__period_title_Long-term (LT) Period (Weeks 24-102),2.1407298555533603e-10,categorical
cat__period_title_Week 0-26 (Main Period),2.1287066273021862e-10,categorical
cat__reason_Site Closure,2.1000969640981075e-10,categorical
cat__reason_Physician Refused to Continue Treatment,2.0606637422296535e-10,categorical
cat__period_title_Treatment Period 1 (Day 1 to Week 15),2.0060207365715285e-10,categorical
"cat__period_title_Double Blind (Treatment Period, 8 Weeks)",1.8876750485347714e-10,categorical
cat__period_title_Phase B (Weeks 24 to 54),1.80620654582794e-10,categorical
cat__reason_Non-compliance with Study Drug,1.801635695218696e-10,categorical
cat__reason_Entry criteria not met,1.780367162784846e-10,categorical
cat__period_title_52 Week (Long Term),1.774167133895021e-10,categorical
cat__period_title_Coadministration Period,1.7668891339250348e-10,categorical
cat__reason_Withdrawal by consent,1.7084208073605624e-10,categorical
cat__period_title_12-Month Clinical Follow-up,1.659497810306099e-10,categorical
cat__period_title_Randomised Treatment Period,1.6296126092419187e-10,categorical
cat__period_title_Randomization (Visit 2),1.624406988834529e-10,categorical
cat__reason_Early intrauterine fetal death,1.6201656908727953e-10,categorical
cat__period_title_Phase A (Up to 24 Weeks),1.6177936719434173e-10,categorical
cat__reason_patient's refusal to come,1.6153951633661766e-10,categorical
cat__period_title_30-day Safety Follow-up Period,1.6023962060418667e-10,categorical
cat__arm_id_FG009,1.585365944844202e-10,categorical
cat__reason_Patient Moved,1.5776664284292323e-10,categorical
cat__reason_Investigator Site Closed,1.5760210789016637e-10,categorical
cat__reason_Personal Reasons,1.573107607470307e-10,categorical
cat__period_title_Single Blind Period (1 Week),1.5666905926133414e-10,categorical
cat__reason_Consent withdrawn by Parent/Guardian,1.539073527934434e-10,categorical
cat__period_title_Period 2：Open-label Period,1.511658651739312e-10,categorical
cat__reason_Subject No Longer Meets Study Criteria,1.4854000979351846e-10,categorical
cat__period_title_Double-blind:Randomized Period (8 Weeks),1.4452722373539693e-10,categorical
cat__reason_Baseline IVUS determined unevaluable,1.407236026902409e-10,categorical
cat__period_title_Week 27 to 52,1.4072144394537182e-10,categorical
cat__period_title_Week 24,1.4022486259084664e-10,categorical
"cat__period_title_Open-Label Extension, 18 Months",1.3511845592348632e-10,categorical
cat__period_title_Phase B (Week 25 to Week 52),1.2970127352914918e-10,categorical
cat__period_title_ST Period,1.29671780701281e-10,categorical
cat__reason_Termination of Study/Site by GSK,1.2920315383777213e-10,categorical
cat__period_title_Treatment Period (Week 0 to 52),1.2614512289731704e-10,categorical
cat__reason_Related to Study Drug administration,1.26087181163012e-10,categorical
cat__reason_Sponsor Decision,1.2510019455449632e-10,categorical
"cat__period_title_3-Single-blind, Single Treatment",1.24342187668152e-10,categorical
cat__reason_Personal Reason,1.2190503675575057e-10,categorical
cat__period_title_Completed the Study Through Week 24,1.2117938835028465e-10,categorical
cat__period_title_Open-label Lead-in Period (Week 0 - 36),1.2084338279389194e-10,categorical
cat__period_title_Double Blind Base Study,1.2005149120251897e-10,categorical
cat__period_title_Treatment Period I (Week 1 to Week 12),1.1968248637440577e-10,categorical
cat__reason_Participant Unavailability,1.1915905434639355e-10,categorical
cat__reason_Did not Enter Follow-up Period,1.151422620471909e-10,categorical
"cat__period_title_Open-Label Extension, Week 26-78",1.1242031607077767e-10,categorical
cat__period_title_Main: Week 0 to 52 (NN1250-3579),1.123473651351022e-10,categorical
"cat__period_title_Treatment Period, 12 Weeks",1.1140837946493033e-10,categorical
cat__reason_Study Terminated by Sponsor,1.1078244710056076e-10,categorical
cat__period_title_Antithrombotic Part (Double Blind),1.0557686384688626e-10,categorical
cat__reason_Unable to Complete,1.0371801453782933e-10,categorical
cat__arm_id_FG015,1.0331378349177917e-10,categorical
cat__period_title_Double Blind Phase,9.930086551562803e-11,categorical
cat__period_title_Short Term (ST) Period,9.858690214237273e-11,categorical
cat__reason_Event related to cardiac condition,9.720311305936618e-11,categorical
cat__period_title_Randomization,9.7096207353052e-11,categorical
cat__period_title_Short-term Period (Day 1 to Week 24),9.424169234111425e-11,categorical
cat__period_title_Active Comparison Phase,9.13976933825932e-11,categorical
cat__reason_Withdrawal by parent/guardian,9.11732217933313e-11,categorical
cat__reason_Administrative problems,8.993536871842818e-11,categorical
cat__reason_Intraoperative exclusion criteria,8.904547646749615e-11,categorical
cat__period_title_Follow-up (FU) Period,8.801870607649337e-11,categorical
cat__period_title_Period 4: Open Label,8.342285634118398e-11,categorical
cat__period_title_Follow-up,8.340086065670342e-11,categorical
cat__period_title_Maintenance Period (26 Weeks),8.056136518945866e-11,categorical
cat__reason_scientific integrity issue,7.754752985015833e-11,categorical
cat__reason_Non-compliant with study medication,7.74113505730798e-11,categorical
cat__reason_Hospitalization due to surgery,7.737144214608039e-11,categorical
cat__reason_Personal and Familial Reason,7.508170260668732e-11,categorical
cat__period_title_Re-randomised Period: Week 56 to Week 68,7.374071254074631e-11,categorical
cat__reason_Familial and personal reasons,6.920993518429852e-11,categorical
cat__period_title_Pre-treatment Period,6.85189697670718e-11,categorical
cat__period_title_Long-term Period (Weeks 24 to 52),6.661489911977677e-11,categorical
cat__period_title_Long Term Double Blind (LTDB),6.608439863290758e-11,categorical
cat__period_title_Up to Interim Analysis (Week 12),6.600746233908221e-11,categorical
cat__reason_No longer met criteria,6.499154195622367e-11,categorical
cat__reason_Non compliant with the protocol,6.090419066261059e-11,categorical
cat__reason_Did not Receive Intervention,5.992509279855218e-11,categorical
"cat__period_title_Extension Period, Weeks 26-52",5.984127309384289e-11,categorical
cat__reason_Participant Decision,5.91367939835215e-11,categorical
cat__reason_Efficacy outcome reached,5.899470648355252e-11,categorical
cat__reason_Previous enrolment into this study,5.6288957160864695e-11,categorical
cat__period_title_Initiation Period (Week 0-26),5.5759883715425714e-11,categorical
"cat__period_title_PeriodI-II (Randomized, Double-Blind)",5.469201183383233e-11,categorical
cat__arm_id_FG011,5.467429676319625e-11,categorical
cat__reason_Not treated,5.4455084423944763e-11,categorical
cat__period_title_Off Drug Follow-up Period (Weeks 56-68),5.440701289596433e-11,categorical
cat__period_title_Treatment Period 1,5.346855400633228e-11,categorical
cat__period_title_Extension Stage,5.323390057910408e-11,categorical
cat__period_title_Maintenance Period 1 (36 Weeks),5.243410611125921e-11,categorical
"cat__period_title_Post Treatment Follow-Up, 3 Months",5.1922330788811686e-11,categorical
cat__reason_No longer meet study criteria,5.170749560819089e-11,categorical
cat__period_title_Valsartan Run-in Period,5.093425977482406e-11,categorical
cat__reason_No longer meets study criteria,4.973314213737091e-11,categorical
cat__reason_Consent Withdrawn,4.9731945183388595e-11,categorical
cat__period_title_Part 2: Open-label Period,4.876368683534618e-11,categorical
cat__reason_24 hr ABPM not enough readings,4.853975669150032e-11,categorical
cat__period_title_Short-Term (ST) Treatment Period,4.680653839219444e-11,categorical
cat__period_title_Extension Phase: 53 - 104 Weeks,4.613501112083759e-11,categorical
cat__reason_Administrative Error,4.517234332534203e-11,categorical
"cat__period_title_Double-Blind, Week 0-26",4.334106062166392e-11,categorical
cat__reason_Specified category,4.110914860736093e-11,categorical
cat__reason_Screen failure,4.091738536529676e-11,categorical
cat__period_title_Core Phase,4.028484424810334e-11,categorical
cat__period_title_Double-blind Treatment (Weeks 1 to 8),3.997013572587698e-11,categorical
cat__reason_Unable to attend termination visit,3.881377803984575e-11,categorical
cat__period_title_Period 2,3.827033067373686e-11,categorical
cat__period_title_50-Week Extension Study,3.7701462155622e-11,categorical
cat__reason_Patient's request,3.760771804575755e-11,categorical
cat__reason_Mis-randomized,3.7237783546459306e-11,categorical
cat__period_title_Long-Term (LT) Treatment Period,3.6091248741294144e-11,categorical
cat__reason_Decision by sponsor,3.581995830594774e-11,categorical
cat__reason_Administrative issue,3.493482170160252e-11,categorical
cat__reason_Non-compliance with protocol,3.447767586299327e-11,categorical
cat__reason_Closed Site,3.307220223437299e-11,categorical
cat__reason_Investigator's Discretion,3.2395948297782526e-11,categorical
cat__reason_Procedure,3.2172724077782726e-11,categorical
cat__period_title_Crossover Period,3.1548629685595617e-11,categorical
cat__period_title_Treatment (12 +/- 2 Days),3.087311858420192e-11,categorical
cat__reason_Missing Weight at Week 176,3.070701631302488e-11,categorical
cat__period_title_Main: Week 0 to 52 (NN1250-3582),3.0538910917030376e-11,categorical
cat__period_title_Period 2: Long-term (52-week) Phase,3.04717338886326e-11,categorical
cat__reason_Randomized but not treated,3.043986179271627e-11,categorical
cat__reason_Lack of Interest,2.935975069828966e-11,categorical
cat__reason_Disallowed Concurrent Medication,2.916741540945797e-11,categorical
cat__reason_Needed excluded medication,2.9016444057481546e-11,categorical
cat__reason_Technical problems,2.896711663736052e-11,categorical
cat__reason_Inadequate Control of IOP,2.8949146311639064e-11,categorical
cat__period_title_Extension (Weeks 9 to 52),2.8364542248664465e-11,categorical
cat__period_title_Follow-up (30 (+ 5) Days),2.7223625661521044e-11,categorical
cat__period_title_Main Phase (26 Weeks),2.5981860442419155e-11,categorical
cat__period_title_2nd Stage,2.5976476288328422e-11,categorical
cat__period_title_4-Randomized Double-blind 2 Treatments,2.5606727179608858e-11,categorical
cat__period_title_Extension: Week 53 to 78 (NN1250-3667),2.5565650542253383e-11,categorical
cat__reason_Had other reason,2.4777734014005907e-11,categorical
cat__period_title_Week 26-52 (Extension Period 1),2.466601885142759e-11,categorical
cat__period_title_Second Period (Additional Drug Added),2.3109299796586256e-11,categorical
cat__reason_Study Closed/terminated,2.2485318426960456e-11,categorical
cat__reason_Lack of Efficacy-Loss of Glucose Control,2.1870747397901045e-11,categorical
cat__reason_Severe non-compliance to protocol,2.1764199017927348e-11,categorical
cat__reason_Lab Abnormality,2.031949379858056e-11,categorical
cat__reason_Subject request to discontinue treatment,1.9453080061143594e-11,categorical
cat__reason_Related to auto-injector administration,1.8670270001917885e-11,categorical
cat__reason_Non-Compliance,1.7681804810628226e-11,categorical
cat__period_title_Weeks 1-8 / 10 mg Dose Level,1.7652511514963314e-11,categorical
cat__period_title_Long-term Period (Weeks 24 to 102),1.7479543802093257e-11,categorical
cat__period_title_Crossover Washout,1.7357343848594183e-11,categorical
cat__reason_Study Site Terminated by Sponsor,1.683336936869023e-11,categorical
cat__period_title_Follow-up Period (FUP),1.6408284313588018e-11,categorical
cat__period_title_Part 2 Single-Blind,1.592562393684201e-11,categorical
"cat__reason_Moved, transfer abroad, did not enter FU",1.5497217967678798e-11,categorical
cat__reason_Poor / Non-compliance,1.4739287166318654e-11,categorical
cat__period_title_Phase A to Phase B Transition Period,1.4389194935639184e-11,categorical
cat__reason_Progressive disease,1.4297263573030368e-11,categorical
cat__period_title_Open-label Treatment Period,1.429379762045419e-11,categorical
cat__reason_Reason other than those specified,1.3943762192055868e-11,categorical
cat__reason_Loss of glucose control,1.389839549546567e-11,categorical
cat__reason_Missing,1.3883647376596288e-11,categorical
cat__period_title_Crossover Washout Period,1.3044885212896425e-11,categorical
cat__reason_Laboratory Adverse Event,1.2857696006087722e-11,categorical
cat__reason_No-compliant subject,1.2842437542536531e-11,categorical
cat__period_title_Phase B - (Week 25 to 52),1.2706324565694838e-11,categorical
cat__period_title_Short-term (ST) Period (Day 1-Week 24),1.2132520704944458e-11,categorical
cat__reason_Exclusion criteria met,1.2068636327830204e-11,categorical
cat__period_title_Extension Treatment Period,1.1868516426098098e-11,categorical
cat__reason_Need for Excluded Med. Discon. Criteria,1.170117882084846e-11,categorical
cat__reason_Not meet/no longer meets criteria,1.1028348164798737e-11,categorical
cat__reason_Entry Criteria Not Met,1.1007566338824024e-11,categorical
cat__period_title_Start Period2 to End Period2 (Week 7-33),1.0777273068997578e-11,categorical
cat__reason_Incorrect enrolment/mis-randomisation,1.0618745732201887e-11,categorical
cat__period_title_Extension,1.0076087486618152e-11,categorical
cat__period_title_Extension: Week 53 to 104 (NN1250-3643),1.0009924715069395e-11,categorical
cat__period_title_Start Period1 to End Period1 (Week 1-6),9.714534220415678e-12,categorical
cat__period_title_Double-blind Treatment Period,9.027117929110402e-12,categorical
cat__reason_Dev. of study spec. withdrawal criteria,8.776339487957326e-12,categorical
cat__reason_Worsening of Glycosolated Hemoglobin,8.395215635342929e-12,categorical
"cat__reason_Captured as ""Other""",8.292950582409633e-12,categorical
cat__reason_Consent withdrawn:Final VS not available,7.2333213224189e-12,categorical
cat__reason_Woman of Child-bearing Potential,6.950125472746804e-12,categorical
cat__reason_Treatment Non-compliance,6.789508907801182e-12,categorical
cat__period_title_Extension Phase (26 Weeks),6.7809292180509395e-12,categorical
cat__reason_Subject decision (vital status: missing),6.701883810655023e-12,categorical
cat__reason_Incorrect enrollment,6.622083114936382e-12,categorical
cat__reason_Sponsor's decision,6.576852633568656e-12,categorical
cat__period_title_Phase A (Weeks 0 to 24),6.496526601390805e-12,categorical
cat__reason_IVUS not available,6.437812125375739e-12,categorical
cat__period_title_Period 1：Double Blind Period,6.06917387274632e-12,categorical
cat__reason_Abnormal Test Procedure Result,6.050098241929032e-12,categorical
cat__reason_Subject no longer meets study criteria,5.892625238652695e-12,categorical
cat__reason_Administrative,5.8610260629057736e-12,categorical
cat__period_title_Referral Screening Period,5.728017450957217e-12,categorical
cat__reason_Lost to follow up,5.723566495033577e-12,categorical
cat__period_title_Phase 1 - Amlodipine+Olmesartan,5.452672057416742e-12,categorical
cat__reason_Lack of glycaemic control,5.325420231286577e-12,categorical
cat__reason_Poor/Noncompliance,5.085804878146385e-12,categorical
cat__reason_Sponsor decision,4.789583839696633e-12,categorical
cat__reason_Subject decision (vital stat: unkn),4.633266937108878e-12,categorical
cat__period_title_Started Study Medication,4.426354962083946e-12,categorical
cat__reason_conmed-BP-pulse-ABPM withdrawal criteria,4.395659929797119e-12,categorical
cat__period_title_Part 3 Double-Blind Withdrawal,4.3249862316517006e-12,categorical
cat__reason_LDL < 50 mg/dL,4.305269216980246e-12,categorical
cat__reason_Treatment Noncompliance,4.253539836961798e-12,categorical
cat__reason_Reason Not Specified: No 30-day visit,4.24297908716459e-12,categorical
cat__reason_Laboratory abnormality,4.194246492925672e-12,categorical
cat__reason_Excluded Medication,4.1906471726276235e-12,categorical
cat__reason_Unsatisfactory therapeutic response,4.1379642381048955e-12,categorical
cat__period_title_Extension Study,4.111512406481699e-12,categorical
cat__period_title_Open-Label Extension Phase,3.888350828544575e-12,categorical
cat__reason_Hypoglycaemia,3.678076401733659e-12,categorical
cat__period_title_Safety Follow Up Period,3.5667249653131585e-12,categorical
cat__reason_Protocol Deviation,3.541720196758558e-12,categorical
cat__arm_id_FG008,3.455840155253589e-12,categorical
cat__period_title_Week 52-78 (Extension Period 2),3.406234808511454e-12,categorical
cat__reason_Study termination,3.4002743886260458e-12,categorical
cat__reason_Site Terminated,3.286139526138214e-12,categorical
cat__reason_Study drug intolerance,3.2367339929391115e-12,categorical
cat__reason_Randomized But Not Treated,3.1402820346067464e-12,categorical
cat__period_title_2-Randomized Double-blind 3 Treatments,3.117747897087764e-12,categorical
cat__reason_Withdrew consent,3.067562545414863e-12,categorical
cat__reason_Poor non-compliance,3.0382203280543803e-12,categorical
cat__reason_Noncompliance with study drug,2.9088814419603154e-12,categorical
cat__period_title_Washout Period (8 Weeks),2.6403122380991774e-12,categorical
cat__reason_Abnormal laboratory value(s),2.474046460376723e-12,categorical
cat__reason_Not Reported,2.4570198777224456e-12,categorical
cat__reason_Sponsor Terminated Study Treatment,2.3440164066923927e-12,categorical
cat__reason_non-specified,2.3272553677900632e-12,categorical
cat__reason_Site Closed Early,2.089150149067419e-12,categorical
"cat__reason_Other, not specified",1.9857622663393555e-12,categorical
cat__reason_Poor compliance or noncompliance,1.982607327686415e-12,categorical
cat__reason_Participant no longer meets study criteria,1.752409729650719e-12,categorical
cat__reason_Restricted med,1.7425153050800072e-12,categorical
cat__period_title_Weeks 13-16 / 40mg Dose Level,1.7120656884431062e-12,categorical
cat__reason_Multiple different reasons,1.6080770384151855e-12,categorical
cat__period_title_Open-label Period,1.5710677268730552e-12,categorical
cat__reason_Condition no longer requires study drug,1.5040723767557826e-12,categorical
cat__period_title_Week 0 to Week 26,1.3847599397289333e-12,categorical
cat__reason_Administrative reason by sponsor,1.3517629888425525e-12,categorical
cat__reason_Administrative reasons,1.2438603286954547e-12,categorical
cat__reason_Hypoglycemia,1.2152835437074744e-12,categorical
cat__reason_Non-Compliance With Study Drug,1.1344000266134526e-12,categorical
cat__reason_Patient Missed Week 72 Visit Due to SAE,1.108384329682746e-12,categorical
cat__reason_Lost to Follow-up for Mortality,1.0448024460852912e-12,categorical
cat__reason_Participant moved,1.0345442212053596e-12,categorical
cat__reason_Creatinine or eGFR withdrawal criteria,1.0171599651982566e-12,categorical
cat__reason_Randomized but not Treated,1.0137229069516437e-12,categorical
cat__period_title_Period V (Double -Blind),9.791624265872207e-13,categorical
cat__period_title_Weeks 9-12 / 20mg Dose Level,8.763109070651208e-13,categorical
cat__reason_Randomized but drug not received,8.645170381858518e-13,categorical
cat__reason_protocol non-compliance,8.51899143336485e-13,categorical
cat__reason_Randomised in error; pregnancy; moving,7.843526528030154e-13,categorical
cat__reason_Reason 'Other' in the protocol,7.127727757136517e-13,categorical
cat__reason_Lab value,6.779955531314992e-13,categorical
cat__reason_Met discontinuation criteria,6.720249775120677e-13,categorical
cat__period_title_Long Term Extension (Up to 25 Jun 2013),6.661982237291531e-13,categorical
cat__reason_Non-Compliance with Study Drug,6.572573302888136e-13,categorical
"cat__reason_Creatinine, or eGFR withdrawal criteria",6.476204580944511e-13,categorical
"cat__period_title_Period 3: Double-blind, Withdrawal",5.765620228211405e-13,categorical
cat__reason_Other discontinuation,5.568129751397959e-13,categorical
cat__reason_Safety reasons,5.271687664079453e-13,categorical
cat__reason_Protocol violation,4.890249011200858e-13,categorical
cat__reason_Laboratory test,4.819538040281435e-13,categorical
cat__reason_Familial and Personal Reasons,4.807837756332619e-13,categorical
cat__reason_Requirement for restricted medication,4.801761090003252e-13,categorical
cat__reason_Lack of trial product,4.707313485668855e-13,categorical
cat__reason_Termination of Study/ Site by GSK,4.673696068993531e-13,categorical
cat__reason_Subject decision/No wish to continue,4.268996329862113e-13,categorical
cat__reason_Personal Circumstance,4.196646397929472e-13,categorical
cat__reason_Use of prohibited medication,3.4101782195597817e-13,categorical
cat__reason_Bariatric Surgery,3.159883710110724e-13,categorical
cat__reason_Poor/noncompliance,3.086149640597911e-13,categorical
cat__reason_Creatinine / Creatinine clearance,3.002829232216225e-13,categorical
cat__reason_Investigator's decision,2.4220263157487243e-13,categorical
cat__reason_Ineligibility determined,2.1894969914200175e-13,categorical
cat__reason_Study Site Reason,2.1617142892963723e-13,categorical
cat__period_title_Randomized Participants,2.0233607991476647e-13,categorical
cat__reason_Missed visit,1.8821294834924527e-13,categorical
cat__reason_Severe non-compliance,1.6979472777495448e-13,categorical
"cat__reason_The subject was randomized, but did not take any investigational product",1.5373459343451256e-13,categorical
cat__reason_Investigator/Orthopedic Surgeon Decision,1.4461194957569392e-13,categorical
cat__period_title_Placebo-controlled Withdrawal Phase,1.2045615833196935e-13,categorical
cat__reason_Early withdraw,1.1345255640064415e-13,categorical
cat__reason_Administrative Reason by Sponsor,1.083141687237145e-13,categorical
cat__reason_Missing disposition information,1.0710207635125111e-13,categorical
cat__reason_Requested discontinue treatment,1.0436045988433768e-13,categorical
"cat__reason_Inv Decision, HbA1c not controlled",1.0311418587217739e-13,categorical
cat__reason_Other contraindicated medication,9.832243121773874e-14,categorical
cat__reason_Randomized in Error - No Study Drug,9.592054181388833e-14,categorical
cat__period_title_Period 2 - Double-Blind Dose Response,9.441200354935267e-14,categorical
cat__reason_Did not meet trial criteria,9.149173463925289e-14,categorical
cat__reason_Serious Adverse Event,4.9922397924990423e-14,categorical
cat__period_title_Period IV (Double-Blind),4.1549799696021685e-14,categorical
cat__reason_Closure of the trial site,3.4447154999232005e-14,categorical
cat__reason_Site not agree to continue after May08,3.214869249548608e-14,categorical
cat__reason_site terminated,3.1805210379317963e-14,categorical
cat__reason_non compliance,3.0192276803562536e-14,categorical
cat__reason_Subject noncompliance,2.7938412576795853e-14,categorical
cat__reason_Drop out before Treatment Start,2.7553059733577907e-14,categorical
cat__arm_id_FG010,2.1321896577697467e-14,categorical
cat__reason_protocol discontinuation criteria,1.9543371804838485e-14,categorical
cat__reason_Abnormal laboratory values,1.7591061673832924e-14,categorical
cat__reason_One or more non-interpretable scan,1.7396184513840176e-14,categorical
cat__reason_Excluded medication,1.7210728371071718e-14,categorical
cat__period_title_Start Period3 to End Period3(Week 34-53),1.3371868603810555e-14,categorical
cat__arm_id_FG013,1.2516092801186828e-14,categorical
cat__reason_No treatment given,9.562492736184095e-15,categorical
cat__reason_Protocol deviation(s),8.835722534420502e-15,categorical
cat__reason_Site Closed by Sponsor,5.64365006223227e-15,categorical
cat__reason_Protocol driven decision point,4.914996017002508e-15,categorical
cat__reason_Taken inhibition medication eg Prandin,4.222377307609862e-15,categorical
cat__period_title_Completed the Study,3.457251220695702e-15,categorical
cat__reason_Administrative reason,1.7646700193261725e-15,categorical
cat__reason_Subject did not meet end of study ABPM,1.407029691039528e-15,categorical
cat__reason_Change in treatment,1.1032343989547143e-15,categorical
cat__arm_id_FG023,2.942155536758403e-16,categorical
cat__arm_id_FG012,1.1619973104021666e-16,categorical
cat__reason_Participant convenience,6.548096186176001e-17,categorical
cat__reason_Study termination by sponsor,5.1063159167955156e-17,categorical
cat__reason_Not Treated,0.0,categorical
cat__reason_Other (Not specified),0.0,categorical
cat__reason_Other (Missing),0.0,categorical
cat__reason_Non-compliant,0.0,categorical
"cat__reason_Non-compliance, not met criteria etc.",0.0,categorical
"cat__reason_Non-compliance, not Met Study Criteria",0.0,categorical
cat__reason_Non-compliance with the CTP,0.0,categorical
cat__reason_Non-compliance with study treatment,0.0,categorical
cat__reason_Non-compliance with study schedule,0.0,categorical
cat__reason_Non-compliance with study procedures,0.0,categorical
cat__reason_Non-compliance with study drug,0.0,categorical
cat__reason_Non-compliance with protocol by the subject,0.0,categorical
cat__reason_Non-compliance with Study Schedule,0.0,categorical
cat__reason_Not Met Study Criteria,0.0,categorical
cat__reason_Not Evaluable for Angiography Analysis,0.0,categorical
cat__reason_Not Evaluable for 9-Month Angiography,0.0,categorical
cat__reason_Orthopedic Surgery,0.0,categorical
cat__reason_Option selected by investigator,0.0,categorical
cat__reason_Open-Label AHA Treatment Requested,0.0,categorical
cat__reason_Open label clopidogrel required,0.0,categorical
cat__reason_Ongoing in Period 2,0.0,categorical
cat__reason_Ongoing,0.0,categorical
cat__reason_One of the subjects IS NO LONGER USING AQUACEL STANDARD OF CARE AND WAS REMOVED FROM THE STUDY,0.0,categorical
cat__reason_Other Reason Not Specified,0.0,categorical
cat__reason_Other Protocol Violation,0.0,categorical
cat__reason_Other Protocol Specified Criteria,0.0,categorical
cat__reason_Other Miscellaneous Reason,0.0,categorical
cat__reason_Other Medical Problems,0.0,categorical
cat__reason_Other Eligibility criteria,0.0,categorical
cat__reason_Other Death,0.0,categorical
cat__reason_Other Complicating Disease,0.0,categorical
cat__reason_Other - Reason not reported in CSR,0.0,categorical
cat__reason_Other - Not Otherwise Specified (NOS),0.0,categorical
cat__reason_Other (house moving),0.0,categorical
cat__reason_Other reason (incl. lack of efficacy),0.0,categorical
cat__reason_Other reason,0.0,categorical
cat__reason_Non-completion of visit activity,0.0,categorical
"cat__reason_Non-compl., not met criteria, etc.",0.0,categorical
cat__reason_Non respect of one of inclusion criteria,0.0,categorical
cat__reason_Non compliant,0.0,categorical
cat__reason_Non compliance with protocol,0.0,categorical
cat__reason_Non compliance,0.0,categorical
cat__reason_Non Serious Hypoglycemia,0.0,categorical
cat__reason_Non Compliance,0.0,categorical
cat__reason_Non-compliant with protocol,0.0,categorical
cat__reason_Non-compliant with Study Medication,0.0,categorical
cat__reason_Non-compliant with Medication,0.0,categorical
cat__reason_Other protocol specified criteria,0.0,categorical
cat__reason_Other prohibited medication,0.0,categorical
cat__reason_Other pre-existing disease worsening,0.0,categorical
cat__reason_Other not specified,0.0,categorical
cat__reason_Other not defined above,0.0,categorical
cat__reason_Other medical condition (no Adverse Event),0.0,categorical
cat__reason_Other listed,0.0,categorical
cat__reason_Other incl. lack of efficacy,0.0,categorical
"cat__reason_Other, Subject moved out of the country",0.0,categorical
"cat__reason_Other, Not Specified",0.0,categorical
cat__reason_Other than stated,0.0,categorical
cat__reason_Other than listed above,0.0,categorical
cat__reason_Other than listed,0.0,categorical
cat__reason_Other reason than stated above,0.0,categorical
cat__reason_Other reason than listed,0.0,categorical
cat__reason_Other reason not described above,0.0,categorical
cat__reason_Other reason for early termination,0.0,categorical
cat__reason_Pain,0.0,categorical
cat__reason_PI recommended early withdrawal,0.0,categorical
cat__reason_PI Decided for Safety Purpose,0.0,categorical
cat__reason_No receive treatment/lost to follow-up,0.0,categorical
cat__reason_No reason provided,0.0,categorical
cat__reason_No primary outcome data,0.0,categorical
cat__reason_No longer required study medication,0.0,categorical
cat__reason_No longer met study criteria,0.0,categorical
cat__reason_No longer meets criteria,0.0,categorical
cat__reason_No longer meeting study criteria,0.0,categorical
cat__reason_Non-compliance towards treatment,0.0,categorical
cat__reason_Non-compliance issues,0.0,categorical
cat__reason_Non-compliance,0.0,categorical
cat__reason_PD: Inconvenience of Dosing,0.0,categorical
cat__reason_PCI at external hospital,0.0,categorical
cat__reason_P.I. recommended due to blood pressure,0.0,categorical
cat__reason_Overall trial ended,0.0,categorical
cat__reason_Outcome event - other,0.0,categorical
cat__reason_Others,0.0,categorical
cat__reason_Other: Not available,0.0,categorical
"cat__reason_Other, weight gain, hypoglycaemic events",0.0,categorical
"cat__reason_Other, not specified above",0.0,categorical
"cat__reason_Other, including non-compliance",0.0,categorical
"cat__reason_Other, Subject wanted HbA1c to be > 7%",0.0,categorical
cat__reason_Participant Thought there were Too Many Adverse Events,0.0,categorical
cat__reason_Participant Schedule,0.0,categorical
cat__reason_Participant Relocating to Africa,0.0,categorical
cat__reason_Participant Randomized but died before dosing,0.0,categorical
cat__reason_Participant Non-compliance,0.0,categorical
cat__reason_Participant Moved to Africa,0.0,categorical
cat__reason_Participant Moved Away,0.0,categorical
cat__reason_Participant Moved,0.0,categorical
cat__reason_Participant Duplicated at Another Site,0.0,categorical
cat__reason_Participant Did Not Come for the Visit,0.0,categorical
cat__reason_Participant Developed a Rash,0.0,categorical
cat__reason_Participant Decided to Move Out of State,0.0,categorical
cat__reason_Participant Could Not Continue Due to Work Related Reasons,0.0,categorical
cat__reason_Parent(s)/guardian(s)'s request,0.0,categorical
cat__reason_Participant moved back to home country,0.0,categorical
cat__reason_Participant missing reason for study discontinuation,0.0,categorical
cat__reason_Participant left the country,0.0,categorical
"cat__reason_Participant is alive, just unable to come for visits",0.0,categorical
cat__reason_Participant had taken prohibited concomitant medication,0.0,categorical
cat__reason_Participant had flushing,0.0,categorical
cat__reason_Participant felt the drug did not work,0.0,categorical
cat__reason_Participant didn't complete MRI,0.0,categorical
cat__reason_Participant did not wish to continue,0.0,categorical
cat__reason_Participant did not take study drug,0.0,categorical
cat__reason_Participant did not receive treatment,0.0,categorical
cat__reason_Participant completed study at visit 27,0.0,categorical
cat__reason_Participant Withdrew Consent,0.0,categorical
cat__reason_Participant tolerability,0.0,categorical
cat__reason_Participant stopped study medication,0.0,categorical
cat__reason_Participant schedule,0.0,categorical
cat__reason_Participant request to discontinue,0.0,categorical
cat__reason_Participant out of assessment window,0.0,categorical
cat__reason_Participant only allowed phone follow-up,0.0,categorical
cat__reason_Participant non-compliance / Protocol violation(s),0.0,categorical
cat__reason_Participant no longer meets the inclusion/exclusion criteria,0.0,categorical
cat__reason_Participant moves,0.0,categorical
cat__reason_Participant moved to another city with no available site,0.0,categorical
cat__reason_Participant moved to Kansas,0.0,categorical
cat__reason_Participant moved out of province,0.0,categorical
cat__reason_Participant moved or relocated,0.0,categorical
cat__reason_Patient Accidentally Unblinded,0.0,categorical
cat__reason_Patient /Family decision,0.0,categorical
cat__reason_Partipant moved away,0.0,categorical
cat__reason_Participation in another ABT-335 trial,0.0,categorical
cat__reason_Participants withdrawn due to company goals,0.0,categorical
cat__reason_Participants request to discontinue study treatment,0.0,categorical
cat__reason_Participants moved,0.0,categorical
cat__reason_Participants Excluded Due to GCP Compliance Issue,0.0,categorical
cat__reason_Participant withdrew consent,0.0,categorical
cat__reason_Participant withdrawn due to COVID-19 situation,0.0,categorical
cat__reason_Participant was in Rehabilitation,0.0,categorical
cat__reason_Participant was Reluctant to Follow-up,0.0,categorical
cat__reason_Participant was Out of the Country,0.0,categorical
cat__reason_Participant wanted to try other therapy or treatment,0.0,categorical
cat__reason_Participant used antipsychosis meds,0.0,categorical
cat__reason_Participant travelled Overseas,0.0,categorical
cat__reason_Patient Refusal,0.0,categorical
cat__reason_Patient Received Glycemic Medication,0.0,categorical
cat__reason_Patient Non-compliant,0.0,categorical
cat__reason_Patient No Longer Requires Study Drug,0.0,categorical
cat__reason_Patient Moving,0.0,categorical
cat__reason_Patient Incorrectly Randomized,0.0,categorical
cat__reason_Patient Disposition Challenges,0.0,categorical
cat__reason_Patient Discontinued for Other Reasons,0.0,categorical
cat__reason_Patient Died,0.0,categorical
cat__reason_Patient Did Not Meet Entrance Criteria,0.0,categorical
cat__reason_Patient Decision Unrelated to AE,0.0,categorical
cat__reason_Patient Decision Unrel to Adverse Event,0.0,categorical
cat__reason_Patient Decision,0.0,categorical
cat__reason_Patient Could Not Return to Hospital Due to COVID-19 Epidemic,0.0,categorical
cat__reason_Patient elected,0.0,categorical
cat__reason_Patient did not wish to attend visits,0.0,categorical
cat__reason_Patient did not attend all visits,0.0,categorical
cat__reason_No More Need of Insulin,0.0,categorical
cat__reason_No Longer Meets Eligibility Criteria,0.0,categorical
cat__reason_No Longer Meets Criteria,0.0,categorical
cat__reason_No 9-Month Angiography Performed,0.0,categorical
cat__reason_New drug pulmonary atrial hypertension,0.0,categorical
cat__reason_New condition or starts new therapy,0.0,categorical
cat__reason_New Drug Pulmonary Atrial Hypertension,0.0,categorical
cat__reason_New Cancer therapy,0.0,categorical
cat__reason_New Antidiabetic Medication,0.0,categorical
cat__reason_Never Entered Follow-up,0.0,categorical
cat__reason_No visit within allowance period,0.0,categorical
cat__reason_No treatment was received,0.0,categorical
cat__reason_Patient deemed ineligible after random,0.0,categorical
cat__reason_Patient declined further treatment,0.0,categorical
cat__reason_Patient decision to stop/interrupt medication,0.0,categorical
cat__reason_Patient decision,0.0,categorical
cat__reason_Patient could not travel to site,0.0,categorical
cat__reason_Patient convenience,0.0,categorical
cat__reason_Patient and PI Decision to Discontinue,0.0,categorical
cat__reason_Patient Uncooperative,0.0,categorical
cat__reason_Patient Still in Follow-up,0.0,categorical
cat__reason_Patient Specific Reasons,0.0,categorical
cat__reason_Patient Self-discontinuation,0.0,categorical
cat__reason_Patient Refused to Continue Study,0.0,categorical
"cat__reason_Patient refusal to continue, not due to AE",0.0,categorical
cat__reason_Patient received Phase A rescue therapy,0.0,categorical
cat__reason_Patient received Empagliflozin for Diabetes,0.0,categorical
cat__reason_Patient randomized in error,0.0,categorical
cat__reason_Patient randomized but not dosed,0.0,categorical
cat__reason_Patient not wish to continue after May08,0.0,categorical
cat__reason_Patient no longer needs study drug,0.0,categorical
cat__reason_Patient needed prohibited treatment,0.0,categorical
cat__reason_Patient moved away/being abroad,0.0,categorical
cat__reason_Patient moved away,0.0,categorical
cat__reason_Patient moved,0.0,categorical
cat__reason_Patient met glycemic withdrawal criteria,0.0,categorical
cat__reason_Per sponsors instruction,0.0,categorical
cat__reason_Per sponsor due to noncompliance,0.0,categorical
cat__reason_Per Sponsors Request,0.0,categorical
"cat__reason_Per Data Query, Less Than 4 Wks Coversyl",0.0,categorical
cat__reason_Patient/guardian decision,0.0,categorical
cat__reason_Patient's no longer requires study drug,0.0,categorical
cat__reason_Patient's Decision Unrelated to AE,0.0,categorical
cat__reason_Patient's Decision,0.0,categorical
cat__reason_Patient withdrew request,0.0,categorical
cat__reason_Patient was randomized due to mistake,0.0,categorical
cat__reason_Patient was non-compliant,0.0,categorical
cat__reason_Patient was early terminated from study,0.0,categorical
cat__reason_Patient was assessed via phone in person,0.0,categorical
cat__reason_Patient uncooperative,0.0,categorical
cat__reason_Physician decision: Day 30 visit <23 day,0.0,categorical
cat__reason_Physician Discontinued-Thrombocytopenia,0.0,categorical
cat__reason_Physical disability to come to the site for the closing visit,0.0,categorical
cat__reason_Personal reasons,0.0,categorical
cat__reason_Personal matter,0.0,categorical
cat__reason_Personal issues,0.0,categorical
cat__reason_Persistent Hyperglycemia,0.0,categorical
cat__reason_Persistant Elevated HbA1c Results,0.0,categorical
cat__reason_Perceived excessive weight loss,0.0,categorical
cat__reason_Poor compliance/noncompliance,0.0,categorical
cat__reason_Poor compliance/Non-compliance,0.0,categorical
cat__reason_Moved to survival status follow-up only,0.0,categorical
cat__reason_Moved out of the country,0.0,categorical
cat__reason_Moved out of the area,0.0,categorical
cat__reason_Moved out of position,0.0,categorical
cat__reason_Moved out of country,0.0,categorical
cat__reason_Moved out of area,0.0,categorical
cat__reason_Moved,0.0,categorical
cat__reason_Move,0.0,categorical
cat__reason_Mostly Lost to Follow Up,0.0,categorical
cat__reason_Morbidity or Mortality primary endpoint,0.0,categorical
cat__reason_Missing/incomplete data,0.0,categorical
cat__reason_Missing study completion information,0.0,categorical
cat__reason_No longer eligible,0.0,categorical
cat__reason_No longer able to take medicines,0.0,categorical
cat__reason_No follow-up data,0.0,categorical
cat__reason_Poor compliance to study protocol,0.0,categorical
cat__reason_Poor compliance,0.0,categorical
cat__reason_Poor Therapeutic Response,0.0,categorical
cat__reason_Poor Glycemic Control,0.0,categorical
"cat__reason_Platelet Count <50,000/mL",0.0,categorical
cat__reason_Planned major surgery,0.0,categorical
cat__reason_Physician's decision,0.0,categorical
cat__reason_Physician decision: No 30-day visit,0.0,categorical
cat__reason_Principle Investigator Decision,0.0,categorical
cat__reason_Principal Investigator Discretion,0.0,categorical
cat__reason_Primary Care Physician Recommendation,0.0,categorical
cat__reason_Potential lost to follow-up,0.0,categorical
cat__reason_Poor/non-compliance,0.0,categorical
cat__reason_Poor/Non-compliance,0.0,categorical
cat__reason_Poor/Non-Compliance,0.0,categorical
cat__reason_Poor or noncompliance,0.0,categorical
cat__reason_Poor or non-compliance,0.0,categorical
cat__reason_Protocol Specific Criteria,0.0,categorical
cat__reason_Protocol Required Discontinuation,0.0,categorical
cat__reason_Protocol Non-compliance,0.0,categorical
cat__reason_Missing data needed for endpt analyses,0.0,categorical
cat__reason_Missing data for participant,0.0,categorical
cat__reason_Missing Primary Outcome,0.0,categorical
cat__reason_Missing Follow-up Status,0.0,categorical
cat__reason_Missing Cooperation,0.0,categorical
cat__reason_Missing Completion Status,0.0,categorical
cat__reason_Missing Active Treatment Status,0.0,categorical
cat__reason_Missed study visits,0.0,categorical
cat__reason_Natural Disaster,0.0,categorical
cat__reason_Mutual consent,0.0,categorical
cat__reason_Protocol Driven Decision Point,0.0,categorical
cat__reason_Protocol Amendment,0.0,categorical
cat__reason_Prolonged duration between visits,0.0,categorical
cat__reason_Prohibited glucose lowering medication,0.0,categorical
cat__reason_Prohibited antiarrhythmic medication,0.0,categorical
cat__reason_Prohibited Concomitant Medication Use,0.0,categorical
cat__reason_Progression of Disease,0.0,categorical
cat__reason_Product quality complaint,0.0,categorical
cat__reason_Procedure Cancelled,0.0,categorical
cat__reason_Psychiatric disorder,0.0,categorical
cat__reason_Provided in CRF for specific reasons,0.0,categorical
cat__reason_Protocol-specified Criteria,0.0,categorical
cat__reason_Protocol-Specific lab discon criteria,0.0,categorical
cat__reason_Protocol-Specific discontinuation,0.0,categorical
cat__reason_Protocol-Spec lab discon criteria,0.0,categorical
cat__reason_Protocol specified discontinuation,0.0,categorical
cat__reason_Protocol required discontinuation,0.0,categorical
cat__reason_Protocol defined stopping criteria,0.0,categorical
"cat__reason_Randomization Criterion #1; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_Randomization Criterion #1,0.0,categorical
"cat__reason_Randomization Criteria #3, #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",0.0,categorical
"cat__reason_Randomization Criteria #3, #4",0.0,categorical
"cat__reason_Randomization Criteria #2, #4",0.0,categorical
"cat__reason_Randomization Criteria #2, #3, #4",0.0,categorical
"cat__reason_Randomization Criteria #2, #3",0.0,categorical
"cat__reason_Randomization Criteria #1, #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
"cat__reason_Randomization Criteria #1, #4",0.0,categorical
"cat__reason_Randomization Criteria #1, #3",0.0,categorical
"cat__reason_Randomization Criteria #1, #2 #4; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
"cat__reason_Randomization Criteria #1, #2",0.0,categorical
"cat__reason_Randomization Crit #1, #4; Withdraw By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_Randomised more than once,0.0,categorical
cat__reason_Ran out of IP and decided to discontinue,0.0,categorical
cat__reason_Randomized but Never Received Study Drug,0.0,categorical
cat__reason_Randomized and not treated,0.0,categorical
cat__reason_Randomized Not Treated,0.0,categorical
cat__reason_Randomization error,0.0,categorical
cat__reason_Randomization Criterion #4; AE,0.0,categorical
"cat__reason_Randomization Criterion #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",0.0,categorical
"cat__reason_Randomization Criterion #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_Randomization Criterion #4,0.0,categorical
cat__reason_Randomization Criterion #3; Physician Decision,0.0,categorical
cat__reason_Randomization Criterion #3; Exceeded 12 Weeks Of Run In,0.0,categorical
"cat__reason_Randomization Criterion #3; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_Randomization Criterion #3,0.0,categorical
cat__reason_Randomization Criterion #2,0.0,categorical
"cat__reason_Randomization Criterion #1; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_Randomization Criterion #1; AE,0.0,categorical
cat__reason_Re-transplant,0.0,categorical
"cat__reason_Re-randomized in part 3, however no drug dispensed",0.0,categorical
cat__reason_Randomized; did not receive intevention,0.0,categorical
"cat__reason_Randomized, not Treated",0.0,categorical
"cat__reason_Randomized, but not treated",0.0,categorical
cat__reason_Randomized in error,0.0,categorical
cat__reason_Randomized in Error,0.0,categorical
cat__reason_Randomized but not exposed,0.0,categorical
cat__reason_Randomized but not dosed,0.0,categorical
cat__reason_Randomized but never treated,0.0,categorical
cat__reason_Randomized but Not Treated,0.0,categorical
cat__reason_Randomized but Not Dosed,0.0,categorical
cat__reason_Reason unspecified,0.0,categorical
cat__reason_Reason unknown,0.0,categorical
cat__reason_Missed Visit - No Phone Contact,0.0,categorical
cat__reason_Missed Visit,0.0,categorical
cat__reason_Missed 12-month visit,0.0,categorical
cat__reason_Missed 12-Month Visit,0.0,categorical
cat__reason_Misrandomized,0.0,categorical
cat__reason_Miscellaneous Reason,0.0,categorical
cat__reason_Mis-randomized (one mis-randomized patient in the Ramipril group also died),0.0,categorical
"cat__reason_Minor bleeding (e.g.,bruising,epistaxis)",0.0,categorical
cat__reason_Minor bleeding,0.0,categorical
cat__reason_Metformin dose haven't decreasd to 2.5 g,0.0,categorical
cat__reason_Met safety criteria for discontinuation,0.0,categorical
cat__reason_Missing reason,0.0,categorical
cat__reason_Reason not reported,0.0,categorical
cat__reason_Reason not provided,0.0,categorical
cat__reason_Reason not listed/blank,0.0,categorical
cat__reason_Reason not given,0.0,categorical
cat__reason_Reason missing,0.0,categorical
cat__reason_Reason Unspecified,0.0,categorical
cat__reason_Reason Unknown,0.0,categorical
cat__reason_Related to Autoinjector Administration,0.0,categorical
cat__reason_Relapse,0.0,categorical
cat__reason_Refused to continue trial medication,0.0,categorical
cat__reason_Refused hospitalization,0.0,categorical
cat__reason_Refused Treatment,0.0,categorical
cat__reason_Refused,0.0,categorical
cat__reason_Recurrent Stroke,0.0,categorical
cat__reason_Recovery,0.0,categorical
cat__reason_Recommendation of Primary Care Physician,0.0,categorical
cat__reason_Received a Kidney Transplant,0.0,categorical
cat__reason_Received Rescue Therapy,0.0,categorical
cat__reason_Run-in failure,0.0,categorical
cat__reason_Run in failure,0.0,categorical
cat__reason_Risk of heart failure,0.0,categorical
cat__reason_Revoked Consent Prior To Procedure,0.0,categorical
cat__reason_Requirement for alternative therapy,0.0,categorical
cat__reason_Requirement for Excluded Medications,0.0,categorical
cat__reason_Required restricted medication,0.0,categorical
cat__reason_Required dialysis,0.0,categorical
cat__reason_Relocation to other city,0.0,categorical
cat__reason_Relocated to Another Country,0.0,categorical
cat__reason_Relocated Out of State,0.0,categorical
cat__reason_Serious Noncompliance,0.0,categorical
cat__reason_Selection criteria finally not met,0.0,categorical
cat__reason_Met blood pressure goal,0.0,categorical
cat__reason_Met Withdrawal Criteria,0.0,categorical
cat__reason_Met Protocol-Defined Stopping Critera,0.0,categorical
cat__reason_Medical reasons by Sponsor,0.0,categorical
cat__reason_Medical history of anemia,0.0,categorical
cat__reason_Medical condition changed,0.0,categorical
cat__reason_Medical advice,0.0,categorical
cat__reason_Maximum clinical benefit,0.0,categorical
cat__reason_Major/minor bleed,0.0,categorical
cat__reason_Machine Failure,0.0,categorical
cat__reason_MRA unsuccessful,0.0,categorical
cat__reason_Missed measurement,0.0,categorical
cat__reason_Missed Visit - Phone Contact f/u,0.0,categorical
cat__reason_Missed Visit - Phone Contact Follow-up,0.0,categorical
cat__reason_Screening failures,0.0,categorical
cat__reason_Screen failure or other uncategorised,0.0,categorical
cat__reason_Screen Failures,0.0,categorical
cat__reason_Screen Failure,0.0,categorical
cat__reason_Schedule Conflict,0.0,categorical
cat__reason_Safety outcome reached,0.0,categorical
cat__reason_Safety concern as judged by the investigator,0.0,categorical
cat__reason_Safety concern as judged by investigator,0.0,categorical
cat__reason_Safety,0.0,categorical
cat__reason_SOURCE DOCUMENT/COORDINATOR MISSING,0.0,categorical
cat__reason_Site Closed by Investigator,0.0,categorical
cat__reason_Site Closed and Subject Withdrew Consent,0.0,categorical
cat__reason_Site Closed Study,0.0,categorical
cat__reason_Site Closed,0.0,categorical
cat__reason_Site 212 removal,0.0,categorical
cat__reason_Significant thrombocytopenia,0.0,categorical
cat__reason_Severe or Repeated Hypoglycaemia,0.0,categorical
cat__reason_Severe non-compliance to the protocol,0.0,categorical
cat__reason_Severe hypoglycaemic episode,0.0,categorical
cat__reason_Severe allergic reaction,0.0,categorical
cat__reason_Serum Potassium Withdrawal Criteria Met,0.0,categorical
cat__reason_Serious haemorrhagic Adverse Event,0.0,categorical
cat__reason_Site cover and participant was not willing to be transferred,0.0,categorical
cat__reason_Site closure:Final VS not available (NA),0.0,categorical
cat__reason_Site closed by investigator,0.0,categorical
cat__reason_Site closed,0.0,categorical
cat__reason_Site Terminated by Sponsor,0.0,categorical
cat__reason_Site Discontinued Study Participation,0.0,categorical
cat__reason_Site Closure/Site Withdrawal,0.0,categorical
cat__reason_Site Closure for Noncompliance,0.0,categorical
cat__reason_Site Closure (Status Unknown),0.0,categorical
cat__reason_Site Closure (Status Alive),0.0,categorical
cat__reason_Site Closing and Withdrew Consent,0.0,categorical
cat__reason_Sponsor's Administrative Decision,0.0,categorical
cat__reason_Sponsor request,0.0,categorical
cat__reason_Sponsor or IRB Decision,0.0,categorical
cat__reason_LostToFollowUpfor3P-MACE(StatusAlive),0.0,categorical
cat__reason_Lost to follow-up for other reasons,0.0,categorical
cat__reason_Lost to Follow-up for Morbidity,0.0,categorical
cat__reason_Lost to FU for 3PMACE:Final VS available,0.0,categorical
cat__reason_Lost to FU for 3P-MACE:Final VS NA,0.0,categorical
cat__reason_Loss of trust,0.0,categorical
cat__reason_Loss of Glucose Control,0.0,categorical
cat__reason_Met protocol-defined stopping criteria,0.0,categorical
"cat__reason_Met inclusion/exclusion, not treated",0.0,categorical
cat__reason_Sponsor discontinued subject or study,0.0,categorical
"cat__reason_Sponsor Termination of Study, etc.",0.0,categorical
cat__reason_Sponsor Request,0.0,categorical
cat__reason_Sponsor Decision on Blinding,0.0,categorical
cat__reason_Site terminated by sponsor,0.0,categorical
cat__reason_Site terminated by Sponsor,0.0,categorical
cat__reason_Site terminated,0.0,categorical
cat__reason_Site prematurely closed by sponsor,0.0,categorical
cat__reason_Study Medication Not Tapered,0.0,categorical
cat__reason_Study Closure,0.0,categorical
cat__reason_Study Close Out,0.0,categorical
cat__reason_Stopped taking study drug,0.0,categorical
cat__reason_Stopped Study Medication,0.0,categorical
cat__reason_Stopped Investigational product (IP) due to an AE in Australia,0.0,categorical
cat__reason_Stop due to diverse problems,0.0,categorical
cat__reason_Started an Exclusionary Medication,0.0,categorical
cat__reason_Start of New Chemotherapy Regimen,0.0,categorical
cat__reason_Spouse underwent surgery and participant was unable to take IP regularly,0.0,categorical
cat__reason_Spontaneous abortion (<20 weeks),0.0,categorical
cat__reason_Sponsor's Decision to End the Study,0.0,categorical
cat__reason_Sponsor's Decision,0.0,categorical
cat__reason_Limited follow-up agreed,0.0,categorical
cat__reason_Less than full participation,0.0,categorical
cat__reason_Less than 6 months on study drug,0.0,categorical
"cat__reason_Late syphilis, latent",0.0,categorical
cat__reason_Last visit outside protocol visit window,0.0,categorical
cat__reason_Lack of treatment efficacy,0.0,categorical
cat__reason_Lack of time,0.0,categorical
cat__reason_Lack of therapeutic effect,0.0,categorical
cat__reason_Lack of efficacy on rescue therapy,0.0,categorical
cat__reason_Lung transplant,0.0,categorical
cat__reason_Low haemoglobin on screening,0.0,categorical
cat__reason_Low Creatinine Clearance,0.0,categorical
cat__reason_Study site excluded from analysis,0.0,categorical
cat__reason_Study ended treatment not available,0.0,categorical
"cat__reason_Study drug stopped, reason missing",0.0,categorical
cat__reason_Study device could not be deployed,0.0,categorical
"cat__reason_Study criteria,compliance,safety, other",0.0,categorical
cat__reason_Study Terminated by Sponsor or Investigator,0.0,categorical
cat__reason_Study Terminated By Sponsor,0.0,categorical
cat__reason_Subject Non-Compliance,0.0,categorical
cat__reason_Subject Moving out of State,0.0,categorical
cat__reason_Subject Moved out of Town,0.0,categorical
cat__reason_Subject Moved,0.0,categorical
cat__reason_Subject Missed the Schedule,0.0,categorical
cat__reason_Subject Migrated to Other Country,0.0,categorical
cat__reason_Subject Left Site Location,0.0,categorical
cat__reason_Subject Defaulted,0.0,categorical
cat__reason_Subject Decision,0.0,categorical
cat__reason_Study-specific discontinuation criteria,0.0,categorical
cat__reason_Study-Specific Withdrawal Criteria,0.0,categorical
cat__reason_Study terminated by Sponsor,0.0,categorical
cat__reason_Subject missed V6.2,0.0,categorical
cat__reason_Subject meets glycemic withdrawal crit.,0.0,categorical
"cat__reason_Subject left town, ran out of study drug",0.0,categorical
cat__reason_Lack of Eligibility,0.0,categorical
cat__reason_Lack of Efficacy-Sub-Reason Exacerbation,0.0,categorical
cat__reason_Lack of Efficacy-No Sub-Reason,0.0,categorical
cat__reason_Lack of Compliance,0.0,categorical
cat__reason_Laboratory adverse event,0.0,categorical
cat__reason_Loss Glucose Control,0.0,categorical
cat__reason_Logistical error study assessments,0.0,categorical
cat__reason_Logistical difficulties,0.0,categorical
cat__reason_Subject decision (vital stat: dead),0.0,categorical
cat__reason_Subject decision (vital stat: alive),0.0,categorical
cat__reason_Subject Withdrawn from Follow-up,0.0,categorical
cat__reason_Subject Required long-term Initiation of Rescue Antihyperglycemic Medication,0.0,categorical
cat__reason_Subject Request To Discontinue Treatment,0.0,categorical
cat__reason_Subject Noncompliance,0.0,categorical
cat__reason_Subject Non-compliance,0.0,categorical
cat__reason_Subject's no longer requires study drug,0.0,categorical
cat__reason_Subject withdrawn-Other,0.0,categorical
cat__reason_Subject withdrawal reason not collected,0.0,categorical
cat__reason_Subject refuse to sign updated consent,0.0,categorical
cat__reason_Subject off study medication,0.0,categorical
cat__reason_Subject non-compliant,0.0,categorical
cat__reason_Subject non-compliance,0.0,categorical
cat__reason_Subject no longer requires study drug,0.0,categorical
cat__reason_Subject moved out of town,0.0,categorical
cat__reason_Subject moved out of state,0.0,categorical
cat__reason_Subject moved,0.0,categorical
cat__reason_Surgery/ procedure,0.0,categorical
cat__reason_Surgery on the Target Limb,0.0,categorical
cat__reason_Surgery / procedure,0.0,categorical
cat__reason_Surgery,0.0,categorical
cat__reason_Supine Hypertension,0.0,categorical
cat__reason_Suicide,0.0,categorical
cat__reason_Subsequent Ineligibility,0.0,categorical
cat__reason_Subjects not reporting status,0.0,categorical
cat__reason_Subjects Without Post-Baseline Assessmen,0.0,categorical
cat__reason_Subjects Did Not Receive Study Drug,0.0,categorical
cat__reason_Subjects Did Not Complete Week 12,0.0,categorical
cat__reason_Subject/guardian Decision,0.0,categorical
cat__reason_Subject/Guardian decision,0.0,categorical
num__evidence_quality,0.0,numeric
cat__reason_Termination of Study by Sponsor,0.0,categorical
cat__reason_Termination of Site by Sponsor,0.0,categorical
cat__reason_Terminated by Sponsor,0.0,categorical
cat__reason_Tendency to low blood glucose levels,0.0,categorical
cat__reason_Technical reason,0.0,categorical
cat__reason_Technical Problems,0.0,categorical
cat__reason_Technical Problem,0.0,categorical
cat__reason_Target dose not tolerated,0.0,categorical
"cat__reason_1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_THE SUBJECT MOVED TO ANOTHER PROVINCE,0.0,categorical
cat__reason_Symptomatic hypotension,0.0,categorical
cat__reason_Switching to other therapy,0.0,categorical
cat__reason_Switch to commercial drug,0.0,categorical
cat__reason_Surgery/Medical Procedure,0.0,categorical
cat__reason_Transferred to palliative care,0.0,categorical
cat__reason_Transferred to hospital closer to home,0.0,categorical
cat__reason_Transferred to another hospital to continue,0.0,categorical
cat__reason_Transferred into RevAssist Program,0.0,categorical
cat__reason_Toxicity,0.0,categorical
cat__reason_Too busy,0.0,categorical
cat__reason_Thromboembolic/outcome event,0.0,categorical
cat__reason_Thromboembolic / outcome event,0.0,categorical
cat__reason_Therapeutic failure/ lack of efficacy,0.0,categorical
"cat__reason_2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",0.0,categorical
cat__reason_The participant quit treatment and study due to their schedule and the final V801 was done remotely,0.0,categorical
cat__reason_The contrast was not seen,0.0,categorical
cat__reason_The blood pressure goal was met,0.0,categorical
cat__reason_The Patient Moved to Another City,0.0,categorical
cat__reason_Triglycerides >800 mg/dL,0.0,categorical
cat__reason_Triglycerides >2000 mg/dL,0.0,categorical
cat__reason_Trial disease worsening,0.0,categorical
cat__reason_Kidney [transplant],0.0,categorical
cat__reason_Issues With Performing Invasive Coronary Angiography (ICA),0.0,categorical
cat__arm_id_FG028,0.0,categorical
cat__arm_id_FG027,0.0,categorical
cat__reason_Investigator's Decision,0.0,categorical
cat__reason_Investigator site closed,0.0,categorical
cat__reason_Investigator removed subject,0.0,categorical
cat__reason_Investigator refused to log temperature,0.0,categorical
cat__reason_Investigator judgement,0.0,categorical
cat__reason_Lack of Trial Compliance,0.0,categorical
cat__reason_Lack of Study Medication Compliance,0.0,categorical
cat__reason_Lack of Response in OL period,0.0,categorical
cat__reason_Trial Terminated ( Site Closed),0.0,categorical
cat__reason_Treatment failure,0.0,categorical
cat__reason_Treatment extension study,0.0,categorical
cat__reason_Treatment discontinuation,0.0,categorical
cat__reason_Treatment Interruption,0.0,categorical
cat__reason_Treatment Failure,0.0,categorical
cat__reason_Treatment Complications,0.0,categorical
cat__reason_Treated but excluded at 1 trial site,0.0,categorical
cat__reason_Transplant planned,0.0,categorical
cat__reason_Transplant,0.0,categorical
cat__reason_Transition to Commercial Treatment,0.0,categorical
cat__reason_Uncontactable by phone,0.0,categorical
cat__reason_Unconfirmed disease progression per investigator,0.0,categorical
cat__reason_Unclassifiable Response,0.0,categorical
cat__reason_Unblinded medication,0.0,categorical
cat__reason_Unable to visit site on schedule,0.0,categorical
cat__reason_Unable to re-enter US,0.0,categorical
cat__reason_Unable to dose reduce per protocol,0.0,categorical
cat__reason_Unable to continue treatment,0.0,categorical
cat__reason_Unable to attend visit,0.0,categorical
cat__reason_Unable to Complete Follow-up,0.0,categorical
cat__reason_Two or more reasons for discontinuation,0.0,categorical
cat__reason_Two consecutive LDL-C <15 mg/dL,0.0,categorical
cat__reason_Various reasons,0.0,categorical
cat__reason_Various,0.0,categorical
cat__reason_Uspecified,0.0,categorical
cat__reason_Used Other Antihypertensive Drug,0.0,categorical
cat__arm_id_FG026,0.0,categorical
cat__reason_Use of Prohibited Medication,0.0,categorical
cat__reason_Use of Excluded Medications,0.0,categorical
cat__reason_Use of Excluded Medication,0.0,categorical
cat__reason_Unsatisfactory Therapeutic Effect,0.0,categorical
cat__reason_Unknown; Reason Not Provided,0.0,categorical
cat__reason_Unknown reasons,0.0,categorical
cat__reason_Unknown reason,0.0,categorical
cat__reason_Underwent aortic root surgery,0.0,categorical
cat__reason_Undefined,0.0,categorical
cat__reason_Withdrawal by Participant,0.0,categorical
cat__reason_Withdrawal by PI for ICA not performed,0.0,categorical
cat__reason_Investigator Not at Site,0.0,categorical
cat__reason_Investigator Discretion,0.0,categorical
cat__reason_Investigator Closed Study at Site,0.0,categorical
cat__reason_Investigational Medicinal Product (IMP) Supply Issues,0.0,categorical
cat__arm_id_FG031,0.0,categorical
cat__reason_Intro of New Anti-Diabetic Medication,0.0,categorical
cat__reason_Intervention by primary care physician,0.0,categorical
cat__reason_Interpretation Failure,0.0,categorical
cat__reason_Intercurrent illness,0.0,categorical
cat__reason_Intercurrent Illness/Medical Condition,0.0,categorical
cat__reason_Lab Abnormality or Adverse Event (AE),0.0,categorical
cat__reason_LDL below 2.59 mmol/L,0.0,categorical
cat__reason_Withdrawal Of Consent,0.0,categorical
cat__reason_Withdrawal By Subject; Withdrawal Of Consent,0.0,categorical
cat__reason_Withdraw of consent on day of random,0.0,categorical
cat__reason_Week 30 not completed due to circumstances surrounding the COVID-19 pandemic,0.0,categorical
cat__reason_Vital Status unknown at study end,0.0,categorical
cat__reason_Vital Status known (alive) at study end,0.0,categorical
cat__reason_Vital Status at study end N/A,0.0,categorical
cat__reason_Visits conflicted with new job,0.0,categorical
cat__reason_Visit Not Performed,0.0,categorical
cat__reason_Violation of Selection Criteria at Entry,0.0,categorical
cat__reason_Withdrawal of Informed Consent,0.0,categorical
cat__reason_Withdrawal of Consent by Subject,0.0,categorical
cat__reason_Withdrawal due to adverse event,0.0,categorical
cat__reason_Withdrawal by proxy/legal representative,0.0,categorical
cat__reason_Withdrawal by patient,0.0,categorical
cat__reason_Withdrawal by participant,0.0,categorical
cat__reason_Withdrawal by Subject and Other,0.0,categorical
cat__reason_Withdrawal by Patient,0.0,categorical
cat__reason_Withdrawal by Participants,0.0,categorical
cat__reason_Withdrawn investigational product,0.0,categorical
cat__reason_Withdrawn from Treatment,0.0,categorical
cat__reason_Withdrawn from Follow-up Participation,0.0,categorical
cat__reason_Withdrawn consent,0.0,categorical
cat__reason_Withdrawn by sponsor's decision,0.0,categorical
cat__reason_Withdrawn by parent/guardian,0.0,categorical
cat__reason_Withdrawn by Sponsor,0.0,categorical
cat__reason_Withdrawn by Mistake,0.0,categorical
cat__reason_Withdrawn before randomisation,0.0,categorical
cat__reason_Withdrawn at Investigator's discretion,0.0,categorical
cat__reason_Withdrawn - does not allow contact,0.0,categorical
cat__reason_Withdrawn,0.0,categorical
cat__reason_Withdrawel criteria,0.0,categorical
cat__reason_Withdrawals between 6 and 24 months,0.0,categorical
cat__reason_clinical progression,0.0,categorical
cat__reason_administrative,0.0,categorical
cat__reason_Worsening serum lipid levels,0.0,categorical
cat__reason_Worsening of liver function,0.0,categorical
cat__reason_Work commitment,0.0,categorical
cat__reason_Wk 16 Efficacy and BP Criteria,0.0,categorical
cat__reason_Withrawal of the consent by the subject,0.0,categorical
cat__reason_Withdrew; No Record on Termination Page,0.0,categorical
cat__reason_Withdrew prior to treatment,0.0,categorical
cat__reason_Withdrew informed consent,0.0,categorical
cat__reason_Withdrew due to being out of the country,0.0,categorical
cat__reason_Withdrew due to Health Condition,0.0,categorical
cat__reason_Withdrew consent prior to randomization,0.0,categorical
cat__reason_lack of efficacy and subject compliance,0.0,categorical
cat__reason_laboratory reporting error,0.0,categorical
cat__reason_issue with vitals prior to dosing,0.0,categorical
cat__reason_investigator/subject decide not continue,0.0,categorical
cat__reason_in prison,0.0,categorical
cat__reason_hyperglycemia that met protocol-specifie,0.0,categorical
cat__reason_hCG positive (not pregnant),0.0,categorical
cat__reason_entry criteria not met,0.0,categorical
cat__reason_discontinue study treatment,0.0,categorical
"cat__reason_did not meet criteria, non-compliance",0.0,categorical
cat__reason_did not finish experimental regimen,0.0,categorical
"cat__reason_concomitant medication,etc.",0.0,categorical
cat__reason_patient intolerance to rescue therapy,0.0,categorical
cat__reason_patient incarcerated,0.0,categorical
cat__reason_other,0.0,categorical
cat__reason_Institutional review board request,0.0,categorical
cat__reason_Initiation Of Protocol-Prohibited Approved PCSK9 Inhibitor,0.0,categorical
cat__reason_Informed consent not signed,0.0,categorical
cat__reason_Informed Consent Recalled by Participant,0.0,categorical
cat__reason_Ineligible,0.0,categorical
cat__arm_id_FG030,0.0,categorical
cat__reason_Ineligibility Determined,0.0,categorical
cat__reason_Increased blood pressure,0.0,categorical
cat__reason_Increased Calcitonin,0.0,categorical
cat__reason_Increase CR from Baseline,0.0,categorical
cat__reason_Incorrectly Randomized,0.0,categorical
cat__reason_Incorrect randomization (not treated),0.0,categorical
cat__reason_Investigator decision,0.0,categorical
cat__reason_Investigator dec./not protocol-related,0.0,categorical
cat__reason_Investigator Stopped Study at Site,0.0,categorical
cat__reason_not treated,0.0,categorical
cat__reason_non-compliance with study procedures,0.0,categorical
cat__reason_non-compliance,0.0,categorical
cat__arm_id_FG029,0.0,categorical
cat__reason_missing treatment disposition pages,0.0,categorical
cat__reason_metformin titrated <1500 mg or >2000 mg,0.0,categorical
cat__reason_lack of motivation,0.0,categorical
cat__reason_responder at visit 4,0.0,categorical
cat__reason_requirement for restricted medication,0.0,categorical
cat__reason_refuse of hospital visit,0.0,categorical
cat__reason_received a kidney transplant,0.0,categorical
cat__reason_reason unspecified,0.0,categorical
cat__reason_randomized in error,0.0,categorical
cat__reason_randomized but not treated,0.0,categorical
cat__reason_questionnaire result not evaluated,0.0,categorical
cat__reason_protocol specific treatment unrelated,0.0,categorical
cat__reason_Abnormal aPPT Levels,0.0,categorical
cat__reason_poor/non-compliance,0.0,categorical
cat__reason_patient scheduled for elective surgery,0.0,categorical
cat__reason_patient moved,0.0,categorical
cat__reason_withdrew prior to dosing,0.0,categorical
cat__reason_withdrawn consent,0.0,categorical
cat__reason_were not scanned,0.0,categorical
cat__reason_use of commercial drug instead of study,0.0,categorical
cat__reason_unclassified,0.0,categorical
cat__reason_unable to collect blood and/or breath,0.0,categorical
cat__reason_treated for 1 day; missing status/reason,0.0,categorical
cat__reason_surgery cancellation,0.0,categorical
cat__reason_supply problems,0.0,categorical
cat__reason_subject no longer meets study criteria,0.0,categorical
cat__reason_sponsor decision,0.0,categorical
cat__reason_Abnormal Test Procedure Result(s),0.0,categorical
cat__reason_site error,0.0,categorical
cat__reason_site closing,0.0,categorical
cat__reason_scans could not be evaluated,0.0,categorical
cat__period_title_30 Days Post-Procedure,0.0,categorical
cat__reason_Incorrect Enrolment,0.0,categorical
cat__reason_Incorrect Enrollment,0.0,categorical
cat__reason_Inclusion/exclusion criteria not met,0.0,categorical
cat__reason_Inclusion/Exclusion Criteria Not Met,0.0,categorical
cat__reason_Incarcerated,0.0,categorical
cat__reason_Impossible to determine HbA1c,0.0,categorical
cat__reason_Implant Not Attempted,0.0,categorical
cat__reason_Implant Attempt Unsuccessful,0.0,categorical
cat__reason_Immobilization Stopped,0.0,categorical
cat__reason_IRB's rejection etc.,0.0,categorical
cat__reason_Insulin Dropped Below Authorized Dose,0.0,categorical
cat__reason_Insufficient therapeutic effect,0.0,categorical
cat__reason_Insufficient Therapeutic Response,0.0,categorical
cat__reason_ID: Benefit/Risk Judgment,0.0,categorical
cat__reason_ICF Withdrawn,0.0,categorical
cat__reason_Hypotension (non-symptomatic),0.0,categorical
cat__reason_Hypoglycaemic events,0.0,categorical
cat__reason_Hypoglycaemia/Hypoglycemia,0.0,categorical
cat__reason_Hyperglycemia rescue,0.0,categorical
cat__reason_Hyperglycemia Discontinuation Criteria,0.0,categorical
cat__reason_Hyperglycemia Criteria,0.0,categorical
cat__reason_Incorrect randomization,0.0,categorical
cat__reason_Incorrect enrolment to study,0.0,categorical
cat__period_title_28-Day Follow-up,0.0,categorical
cat__period_title_10 Year Follow up,0.0,categorical
"cat__period_title_1-Single-blind, Run-in, Single-Treatment",0.0,categorical
cat__reason_Hospitalization (not including surgery),0.0,categorical
cat__reason_Hospice Admission,0.0,categorical
cat__reason_Home monitoring off meds,0.0,categorical
cat__reason_Hip Replacement,0.0,categorical
cat__reason_Guardian decision,0.0,categorical
cat__reason_Glycemic discontinuation criteria,0.0,categorical
cat__reason_Glycemia over 13.3 millimole per litre,0.0,categorical
cat__reason_General Anaesthesia,0.0,categorical
cat__reason_GSPECT at rest was not done,0.0,categorical
cat__reason_IRB request,0.0,categorical
cat__reason_ID: Patient Noncompliance,0.0,categorical
cat__reason_ID: Palliative Treatment Only,0.0,categorical
cat__period_title_9-Month Angiographic Follow-up,0.0,categorical
cat__period_title_5 Year Follow up,0.0,categorical
cat__reason_Flushing Symptoms,0.0,categorical
cat__reason_Fear of hypoglycaemia,0.0,categorical
cat__reason_Fear of experiencing AE again,0.0,categorical
cat__reason_Fasting plasma glucose level increased,0.0,categorical
cat__reason_Fasting plasma glucose >240 mg/dL,0.0,categorical
cat__reason_Fasting Glucose > 240 mg/dL,0.0,categorical
cat__reason_Family request,0.0,categorical
cat__reason_Family or MD withdrew subject,0.0,categorical
cat__reason_Family illness,0.0,categorical
cat__reason_Family Emergency,0.0,categorical
cat__reason_Family Crisis - could not participate,0.0,categorical
cat__reason_Familial or Personal Reasons,0.0,categorical
cat__reason_Hyperglicaemia,0.0,categorical
cat__reason_Hospitalized due to kidney transplant,0.0,categorical
cat__reason_Not Compliant with Study Procedures,0.0,categorical
cat__period_title_Basal Insulin Optimization Phase (BIO),0.0,categorical
cat__period_title_All-IP Period (Years 2 and 3),0.0,categorical
cat__period_title_Double Blind,0.0,categorical
cat__reason_Failure to Return,0.0,categorical
cat__reason_Fails to meet inclusion/exclusion,0.0,categorical
cat__reason_Failing to Meet Randomization Requirements,0.0,categorical
cat__reason_Failed mobilization,0.0,categorical
cat__reason_Failed inclusion criteria #4,0.0,categorical
cat__reason_Failed Inclusion Exclusion Criteria,0.0,categorical
cat__reason_FPG exceeds limits/too high,0.0,categorical
cat__reason_Explanted,0.0,categorical
cat__reason_Exited prior to EP study,0.0,categorical
cat__reason_Exclusion criteria violation,0.0,categorical
cat__reason_Exclusion criteria,0.0,categorical
cat__reason_Not Available for the 8 Week Visit,0.0,categorical
cat__reason_GCP violation,0.0,categorical
cat__reason_GCP non-compliance,0.0,categorical
cat__reason_Flushing with Product,0.0,categorical
cat__reason_Exceeded 12 Weeks Of Run In,0.0,categorical
cat__reason_Error of power injector,0.0,categorical
cat__reason_Erectile dysfunction,0.0,categorical
cat__reason_Entry criterion not met,0.0,categorical
cat__reason_Entry criteria violation,0.0,categorical
cat__reason_Entry Criteria not Met,0.0,categorical
cat__reason_Entered into Another Clinical Trial,0.0,categorical
cat__reason_Entered Rescue Procedure,0.0,categorical
cat__reason_Enrollment capped,0.0,categorical
cat__reason_Enrolled in an investigational study,0.0,categorical
cat__reason_Noncompliant with Study Visits,0.0,categorical
cat__reason_False Treatment,0.0,categorical
cat__reason_Failure to meet continuation criteria,0.0,categorical
cat__reason_Enrolled but no catheter inserted,0.0,categorical
cat__reason_End of study visit not completed/delayed,0.0,categorical
cat__reason_End of study visit completed by phone,0.0,categorical
cat__reason_Eligibility criteria not fulfilled,0.0,categorical
cat__reason_Eligibility Criteria not Fulfilled,0.0,categorical
cat__reason_Eligibility Criteria,0.0,categorical
cat__reason_Elevated triglyceride,0.0,categorical
cat__reason_Elevated LFT results,0.0,categorical
cat__reason_Elevated Creatinine and Potassium levels,0.0,categorical
cat__reason_Noncompliant,0.0,categorical
cat__reason_Early termination by subject,0.0,categorical
cat__reason_Excluded from study,0.0,categorical
cat__reason_Excluded from analysis,0.0,categorical
cat__period_title_Extension Period:26 Weeks(Upto 52 Weeks),0.0,categorical
cat__period_title_Extended Follow-up Cutoff (23 Jul 2008),0.0,categorical
cat__period_title_Enrolled - Long-Term Extension Study,0.0,categorical
cat__period_title_Follow-Up(Week 13/1 Week Post Last Dose),0.0,categorical
cat__period_title_Follow-Up Period - Randomized Patients,0.0,categorical
cat__period_title_Follow up Period - No Drug Treatment,0.0,categorical
cat__period_title_Follow up Period (Week 56-68),0.0,categorical
cat__period_title_Final Follow-up,0.0,categorical
cat__period_title_Extension: Week 27 to 52 (NN5401-3645),0.0,categorical
cat__period_title_LCZ696 Run-in Period,0.0,categorical
cat__period_title_Interphase,0.0,categorical
cat__reason_Early Termination,0.0,categorical
cat__reason_ESKD,0.0,categorical
cat__reason_Dyspnea,0.0,categorical
cat__reason_Due to long-term overseas business trips,0.0,categorical
cat__reason_Due to adaptive design,0.0,categorical
cat__reason_Due to Covid-19 Pandemic,0.0,categorical
cat__reason_Due to COVID 19 restrictions,0.0,categorical
cat__reason_Due to Bariatric surgery,0.0,categorical
"cat__reason_Drug noncompliance,moved,other",0.0,categorical
"cat__reason_Drug noncompliance, other",0.0,categorical
"cat__reason_Drug noncompliance, moved, other",0.0,categorical
"cat__reason_Drug non-compliance, moved, other",0.0,categorical
cat__reason_Enrolled in Long-term Extension Study,0.0,categorical
cat__reason_Enrolled but screen failures,0.0,categorical
cat__reason_Enrolled but not treated,0.0,categorical
cat__reason_Noncompliance with Protocol,0.0,categorical
cat__reason_Diverse Reasons,0.0,categorical
cat__reason_Disease relapse,0.0,categorical
cat__reason_Discontinued in error,0.0,categorical
cat__reason_Discontinued due to DKA/hypoglycemia,0.0,categorical
cat__reason_Discontinued by Sponsor,0.0,categorical
cat__reason_Discontinued at clinical cutoff (due to end of data collection period),0.0,categorical
cat__reason_Discontinued after 41 days Rx,0.0,categorical
cat__reason_Discontinued Prior to Visit,0.0,categorical
cat__reason_Discontinued,0.0,categorical
cat__reason_Discontinuation due to Rash,0.0,categorical
cat__reason_Early study termination,0.0,categorical
cat__reason_Early recovery,0.0,categorical
cat__period_title_Follow-up Through 30 Days Post Procedure,0.0,categorical
cat__reason_Disallowed Concomitant Medication,0.0,categorical
cat__reason_Difficulty Swallowing,0.0,categorical
cat__reason_Difficulty Making it to Study Visit,0.0,categorical
cat__reason_Difficultulty in use of device,0.0,categorical
cat__reason_Dietician consultation >30 days,0.0,categorical
cat__reason_Died,0.0,categorical
cat__reason_Didn't receive study treatment,0.0,categorical
cat__reason_Did not take study treatment,0.0,categorical
cat__reason_Did not take study medication,0.0,categorical
cat__reason_Did not return for end of study visit,0.0,categorical
cat__reason_Did not receive treatment,0.0,categorical
cat__reason_Did not receive randomized treatment,0.0,categorical
cat__reason_Drug non-compliance,0.0,categorical
cat__reason_Drug Holiday,0.0,categorical
cat__period_title_Long-term Extension,0.0,categorical
cat__period_title_Maintencance Period 2 (36 Weeks),0.0,categorical
cat__period_title_Main: Week 0 to 26 (NN5401-3594),0.0,categorical
cat__period_title_Main Phase: 0 - 52 Weeks,0.0,categorical
cat__period_title_Open-Label Extension Period,0.0,categorical
cat__reason_Did not receive allocated intervention,0.0,categorical
cat__reason_Did not receive IV loop diuretics,0.0,categorical
cat__reason_Did not met inclusion criteria,0.0,categorical
cat__reason_Noncompliance to Study Drug,0.0,categorical
cat__reason_Did not meet study criteria,0.0,categorical
cat__reason_Did not meet responder criteria,0.0,categorical
cat__reason_Did not meet eligibility criteria,0.0,categorical
cat__reason_Did not meet criteria before ABPM,0.0,categorical
cat__reason_Did not enter long-term study,0.0,categorical
cat__reason_Did not continue to Period II,0.0,categorical
cat__reason_Did not complete Week 30 assessments due to scheduling conflict,0.0,categorical
cat__reason_Did not attend the termination visit,0.0,categorical
cat__reason_Discontinuation by the subject,0.0,categorical
"cat__reason_Discont. single-blind, Mis- randomized",0.0,categorical
cat__reason_Discharged within 48 hours,0.0,categorical
cat__reason_Did not Entered Follow-up,0.0,categorical
cat__reason_Did Not Wish To Continue,0.0,categorical
cat__reason_Did Not Receive Study Drug,0.0,categorical
cat__reason_Did Not Meet Protocol Eligibility,0.0,categorical
cat__reason_Did Not Meet Entrance Criteria,0.0,categorical
cat__reason_Did Not Meet Eligibility Criteria,0.0,categorical
cat__reason_Diagnosed With Type 1 Diabetes Mellitus,0.0,categorical
cat__reason_Device not implanted,0.0,categorical
cat__reason_Developed discontinuation criteria,0.0,categorical
cat__reason_Did not receive randomized study drug,0.0,categorical
cat__reason_Did not receive investigational product,0.0,categorical
cat__reason_Did not receive any study medication,0.0,categorical
cat__period_title_Open Label,0.0,categorical
cat__reason_Decision by the investigator/sponsor,0.0,categorical
cat__reason_Decision by the Investigator/Sponsor,0.0,categorical
cat__reason_Decision Unrelated to Adverse Event,0.0,categorical
cat__reason_Death/Withdrew/Criteria Violation,0.0,categorical
"cat__reason_Death, prior to treatment",0.0,categorical
cat__reason_Death / Reintervention / Medical Reasons,0.0,categorical
cat__reason_Death (non-related to the study,0.0,categorical
cat__reason_Death (due to adverse events,0.0,categorical
cat__reason_Did not Receive Treatment,0.0,categorical
cat__reason_Did not Receive Study Treatment,0.0,categorical
cat__period_title_Open-label Segment 1,0.0,categorical
cat__period_title_Open-Label Period,0.0,categorical
cat__reason_Noncompliance of scheduled visits,0.0,categorical
cat__reason_Creatinine/CrCl -Increase in creatinine,0.0,categorical
cat__reason_Creatinine or eGFR Discon. Criteria,0.0,categorical
"cat__reason_Creatinine and eGFR, excluded medication",0.0,categorical
cat__reason_Non-specified,0.0,categorical
cat__reason_Creatine increased,0.0,categorical
cat__reason_Covid-19 Non-AE Related Issues,0.0,categorical
cat__reason_Covid-19 Non Adverse Event (AE) Related Issues,0.0,categorical
cat__reason_Covid-19,0.0,categorical
cat__reason_Covid 19,0.0,categorical
cat__reason_Could not take time off work,0.0,categorical
cat__reason_Could not get whole set of images,0.0,categorical
cat__reason_Deep-vein Thrombosis,0.0,categorical
cat__reason_Decreased kidney function,0.0,categorical
cat__reason_Decline to return for GSPECT,0.0,categorical
cat__reason_Contraindication to oral anticoagulant,0.0,categorical
cat__reason_Contraindication,0.0,categorical
cat__reason_Contradiction to study medication,0.0,categorical
cat__reason_Continuing Treatment,0.0,categorical
cat__reason_Continue with therapy available commercially,0.0,categorical
cat__reason_Consistently forgot to bring study drug kits to site visits (for compliance check),0.0,categorical
cat__reason_Consent withdrawn: Final VS available,0.0,categorical
"cat__reason_Consent withdrawn, not due to AE",0.0,categorical
cat__reason_Data entry error (reported as study completion and study discontinuation),0.0,categorical
cat__reason_Creatinine/eGFR,0.0,categorical
cat__reason_Creatinine/Creatinine Clearance Criteria,0.0,categorical
cat__period_title_Phase 2 - Amlodipine+Valsartan,0.0,categorical
cat__reason_Non-serious Hypoglycemia,0.0,categorical
cat__period_title_Period III (Single-Blind),0.0,categorical
cat__reason_Consent Withdrawal,0.0,categorical
cat__reason_Conflicting HbA1c Results at Screening,0.0,categorical
cat__reason_Condition no longer required study drug,0.0,categorical
cat__reason_Concurrent trial enrollment,0.0,categorical
cat__reason_Completed out of Window,0.0,categorical
cat__reason_Completed extension 1 (weeks 26-40),0.0,categorical
cat__reason_Completed Survival Follow-up,0.0,categorical
cat__reason_Completed Phase A Did Not Enter Phase B,0.0,categorical
cat__reason_Comfort care,0.0,categorical
cat__reason_Non-compliant with study treatment,0.0,categorical
cat__reason_Could not attend study visits,0.0,categorical
cat__reason_Could not access randomization system,0.0,categorical
cat__reason_Coordinator error,0.0,categorical
cat__reason_Not treated with Patiromer during Run-in,0.0,categorical
cat__period_title_Phase I,0.0,categorical
cat__period_title_Run-in period,0.0,categorical
"cat__period_title_Run-in Period, Weeks -12-0",0.0,categorical
cat__reason_Clinical efficacy endpoint reached,0.0,categorical
cat__reason_Clinical adverse event,0.0,categorical
cat__reason_Clinical Worsening,0.0,categorical
cat__reason_Clinical Endpoint Reached,0.0,categorical
cat__reason_Clinic closed,0.0,categorical
cat__reason_Clearly not eligible for the study,0.0,categorical
cat__reason_Chest Discomfort,0.0,categorical
cat__reason_Changed job/ran out if meds,0.0,categorical
cat__reason_Not reported,0.0,categorical
cat__reason_Change in RAAS inhibitor therapy,0.0,categorical
cat__reason_Change in Injection Schedule,0.0,categorical
cat__reason_Consent withdrawal,0.0,categorical
cat__reason_Consent Withdrawn (Status Alive),0.0,categorical
cat__period_title_Run-in Period (Week 0 to Week 20),0.0,categorical
cat__period_title_Run-in Period (12 Weeks),0.0,categorical
cat__period_title_Run-in Period,0.0,categorical
cat__period_title_Rerandomization Arm 1 Only,0.0,categorical
cat__reason_Not reconsenting,0.0,categorical
cat__period_title_Randomization Prior to Study Med,0.0,categorical
cat__period_title_Single-Blind Valsartan 160 mg,0.0,categorical
cat__period_title_Single-Blind,0.0,categorical
cat__reason_Carotid or Neurosurgery,0.0,categorical
cat__reason_Cannot contact patient directly,0.0,categorical
cat__reason_Cancer Progression,0.0,categorical
cat__reason_Cancer Cured,0.0,categorical
cat__reason_Calcitonin Out of Range,0.0,categorical
cat__reason_CRC didn't contact participant for FU,0.0,categorical
cat__reason_COVID-19 logistical restrictions,0.0,categorical
cat__reason_Bolus tracking failed,0.0,categorical
cat__reason_Blood Pressure/Potassium Criteria Met,0.0,categorical
cat__reason_Blood Pressure Withdrawal Criteria Met,0.0,categorical
cat__reason_Blood Pressure Not Controlled,0.0,categorical
cat__reason_Bleeding,0.0,categorical
cat__reason_Clinically significant lab abnormalities,0.0,categorical
cat__reason_Clinical worsening event,0.0,categorical
cat__period_title_Screened Vitamin D Deficient,0.0,categorical
cat__period_title_SOC-controlled Period (Year 1),0.0,categorical
cat__reason_Atrial Fibrillation/Flutter recurrence,0.0,categorical
cat__reason_At the subject's own request,0.0,categorical
cat__reason_At the participant's own request,0.0,categorical
cat__reason_At the discretion of the investigator,0.0,categorical
cat__reason_At the Participant's own Request,0.0,categorical
cat__reason_At the Participant's Own Request,0.0,categorical
cat__reason_Assigned treatment by mistake,0.0,categorical
cat__reason_Assessment discrepancy,0.0,categorical
cat__reason_Angiotensin II receptor blocker required,0.0,categorical
cat__reason_Change Insulin Dosage Exceeding Criteria,0.0,categorical
cat__reason_Catheter inserted but did not undergo ablation,0.0,categorical
cat__reason_Casebook Unsigned,0.0,categorical
cat__period_title_Study Treatment Period,0.0,categorical
cat__period_title_Stent Intervention/Randomization,0.0,categorical
cat__reason_Not ready to exercise,0.0,categorical
"cat__reason_Adverse event, serious fatal event",0.0,categorical
"cat__reason_Adverse event, serious fatal",0.0,categorical
"cat__reason_Adverse event, non-fatal",0.0,categorical
cat__reason_Adverse event prior to treatment,0.0,categorical
cat__reason_Adverse event or serious adverse event,0.0,categorical
cat__reason_Adverse event (not hypoglycaemia),0.0,categorical
cat__reason_Adverse Events (unrelated to,0.0,categorical
cat__reason_Adverse Events (treatment-related),0.0,categorical
"cat__reason_Adverse Event, prior to treatment",0.0,categorical
cat__reason_Adverse Event Other than Hyperglycemia,0.0,categorical
"cat__reason_Berotralstat Provided by alternative Means (i.e., Early Access Program or Commercially Available)",0.0,categorical
cat__reason_Not pre-specified/Not coded,0.0,categorical
cat__reason_Administrative reasons by Sponsor,0.0,categorical
cat__reason_Administrative reason by author,0.0,categorical
cat__reason_Administrative reason by Sponsor,0.0,categorical
cat__reason_Not otherwise specified,0.0,categorical
cat__reason_Administrative decision,0.0,categorical
cat__reason_Not due to the above reasons,0.0,categorical
cat__reason_Administrative Problems,0.0,categorical
cat__reason_Administrative Problem,0.0,categorical
cat__reason_Alternative Treatment,0.0,categorical
cat__reason_Alternative Therapy,0.0,categorical
"cat__reason_All death, all MI, all Revascularization",0.0,categorical
cat__reason_Not compliant,0.0,categorical
cat__reason_Not coded/ Not pre-specified,0.0,categorical
cat__reason_Administration reason by sponsor,0.0,categorical
cat__reason_Administration problem,0.0,categorical
cat__reason_Addition of other PAH therapeutic agent,0.0,categorical
cat__reason_Abnormal test proceedure results,0.0,categorical
cat__reason_Abnormal test procedure results,0.0,categorical
cat__reason_Abnormal test procedure result,0.0,categorical
cat__reason_Abnormal labs,0.0,categorical
cat__reason_Not attending study visits,0.0,categorical
cat__reason_Abnormal laboratory value,0.0,categorical
cat__reason_Abnormal laboratory measure,0.0,categorical
cat__reason_Abnormal lab values,0.0,categorical
cat__reason_Adverse Event + Elevated Fasting Glucose,0.0,categorical
cat__reason_Adminstrative,0.0,categorical
cat__arm_id_FG025,0.0,categorical
cat__arm_id_FG024,0.0,categorical
cat__reason_Not attending study visit,0.0,categorical
cat__arm_id_FG022,0.0,categorical
cat__arm_id_FG021,0.0,categorical
cat__arm_id_FG020,0.0,categorical
cat__arm_id_FG019,0.0,categorical
cat__arm_id_FG018,0.0,categorical
cat__arm_id_FG017,0.0,categorical
cat__arm_id_FG016,0.0,categorical
cat__arm_id_FG014,0.0,categorical
cat__reason_Not able to visit the site,0.0,categorical
cat__reason_Administrative Decision,0.0,categorical
cat__reason_Abnormal Test Procedure,0.0,categorical
cat__reason_Abnormal Laboratory values,0.0,categorical
cat__reason_Abnormal Laboratory Value(s),0.0,categorical
cat__reason_Abnormal Laboratory Value,0.0,categorical
cat__reason_Ablation,0.0,categorical
"cat__reason_AE; Withdrawal By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_AE; Withdrawal By Subject,0.0,categorical
cat__reason_AE; Physician Decision,0.0,categorical
"cat__reason_AE; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",0.0,categorical
"cat__reason_AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",0.0,categorical
cat__reason_AE (Adverse Event),0.0,categorical
cat__reason_>=1 reason assigned per patient,0.0,categorical
cat__reason_> Three Moderate Hypoglycemic Episodes,0.0,categorical
